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Abstract 
“Kernicterus” due to hyperbilirubinemia is one of main cause of 
irreversible brain damage in low and middle income countries. Deaths 
due to “kernicterus” are ranked within the top 3 causes of neonatal death 
in African countries. Neonates experiencing permanent or temporary 
absence or reduced activity of Uridine diphosphate-glucuronosyl-
transferase A1 (UGT1A1) enzyme present increased levels of total 
unconjugated bilirubin (UCB) in the blood. When the bilirubin binding 
capacity of serum albumin is saturated, this results in the increase in the 
free fraction of bilirubin (Bf). The excess of Bf is accumulated in lipid-
rich tissues such as the brain, where it may reach toxic levels causing 
bilirubin-induced encephalopathy in jaundiced newborns and patients 
with Crigler-Najjar syndrome Type I, leading to kernicterus if not 
promptly treated. Bilirubin causes severe neurological dysfunction by 
affecting several different cellular pathways such as, induction of 
oxidative stress, endoplasmic reticulum (ER) stress, autophagy, 
neuroinflammation and DNA damage. 
The work done in this thesis focus on the DNA damaging effect of 
bilirubin on neuronal (SH SY 5Y) and non-neuronal (HeLa) cells and 
the effect of bilirubin on the different double stranded break (DSB) 
repair pathways was investigated using HeLa DR GFP and HeLa cell 
lines. 
Bilirubin exposure led to time-dependent increase in DNA damage in 
neuronal cells. Treatment with the anti-oxidant N-acetylcysteine (NAC) 
caused a dose-dependent decrease in DNA damage, suggesting a key 
role of oxidative stress in bilirubin-induced DNA damage. 
In the second part of this work, I studied the effect of bilirubin on 
different DSB repair pathways using HeLa cell lines. Treatment with 
  
xvii 
 
bilirubin modulated Homologous Recombination (HR) in a time-
dependent manner. In fact, treatment with different doses of bilirubin 
led to a dose-dependent increase in HR. Bilirubin-induced increase in 
HR was reversed by addition of NAC, suggesting the important role of 
oxidative stress in bilirubin-induced modulation of HR. DNA damage 
analysis after bilirubin treatment showed an increase in DNA damage in 
HeLa cells. Unexpectedly, bilirubin-induced DNA damage had no effect 
on the cell cycle profile. Similarly, exposure to bilirubin concentrations 
similar to those found in patients led to an increase in the Non-
Homologous End Joining (NHEJ) pathway. These results suggest the 
general increase in DSB repair pathways by bilirubin. 
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1.1 Bilirubin metabolism 
Bilirubin is the final product of heme catabolism in mammals. About 
80% of heme is haemoglobin derived, while the remaining 20% is 
derived from myoglobin and other heme-containing proteins such as 
cytochromes, catalase and peroxidase (Sticova and Jirsa, 2013). It can 
also be generated due to inefficient erythropoiesis in the bone marrow 
(London et al., 1950). Mainly occurring in the reticulo-endothelial 
system, the prosthetic heme groups are oxidized into biliverdin by heme 
oxygenase (HO-1) and then reduced into bilirubin by biliverdin 
reductase (Figure 1). 
 
Figure 1. Metabolism of bilirubin. The structures of heme, biliverdin, 
unconjugated and conjugated bilirubin are shown, along with the enzyme catalysing 
each step. Adapted from (Jangi et al., 2013). 
 
Bilirubin is water insoluble in nature. It circulates in the plasma as 
serum albumin bound form. Unconjugated bilirubin (UCB) is taken 
rapidly by hepatocytes where it is conjugated to glucuronic acid and 
converted into bilirubin mono and diglucuronides by the endoplasmic 
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reticulum localized enzyme UDP-glucuronosyl transferase A1 
(UGT1A1) (Figure 2) (Bosma, 2003; Jangi et al., 2013). Bilirubin 
conjugation increases its solubility and is necessary for its safe disposal 
from the body through the bile fluid, thus, preventing its accumulation 
to toxic levels in plasma and lipid-rich tissues, such as the brain. The 
conjugated form of bilirubin is transported out from hepatocytes to the 
bile fluid by active transporters such as multidrug-associated resistance 
protein 2 (Mrp2 or ABCC2) (Erlinger et al., 2014; Jemnitz et al., 2010; 
Keppler, 2011). Bacterial β-glucuronidase present in the intestine 
partially deconjugates bilirubin, followed by degradation to 
urobilinogen and stercobilinogen, and their respective oxidation 
products (Maki et al., 1962; Maki et al., 1964). A fraction of the 
intestinal bilirubin is absorbed by enterocytes to reach the liver in adults. 
This enterohepatic cycle may contribute to an increase of plasma 
bilirubin in neonates (Vitek and Carey, 2003). Under physiological 
conditions, a significant portion of bilirubin glucuronides enters into the 
blood stream through the ABCC3 transporter followed by re-entry into 
downstream hepatocytes via OATP1B1/3. This process helps to prevent 
the saturation of biliary excretion capacity of upstream hepatocytes (van 
de Steeg et al., 2012). 
 
The liver is the main organ of UGT1A1 expression, although it is also 
found at much lower levels in a few extra-hepatic tissues like kidney, 
intestine and skin (Fisher et al., 2001; Fujiwara et al., 2015; Sumida et 
al., 2013). 
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Figure 2. Bilirubin conjugation in hepatocytes. Bilirubin is conjugated with 
glucuronic acid in the lumen of the endoplasmic reticulum. Bilirubin glucuronides 
are then transported out from the lumen to the cytosol by the bilirubin glucuronide 
efflux transporter. Adapted from (Erlinger et al., 2014). 
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1.2 Hyperbilirubinemia conditions 
Hyperbilirubinemia can be broadly categorised into genetic and non-
genetic types, according to the main causes of the condition: 
 
1.2.1 Genetic hyperbilirubinemia  
 
Crigler-Najjar syndrome type I (CNSI) 
CNSI is a very rare recessive condition affecting about 0.6-1 in 1 
million live newborns. It is caused by mutations in UGT1A1 gene that 
result in the complete absence of the UGT1A1 enzyme. Due to absence 
of UGT1A1, bilirubin glucuronidation does not occur, causing severe 
hyperbilirubinemia, with neurotoxicity followed by death due to 
kernicterus, if untreated (Bosma, 2003; Crigler and Najjar, 1952). 
 
Crigler-Najjar syndrome type II (CNSII) 
CNSII is a milder form of the disease, which is characterised by low 
level or activity of UGT1A1 enzyme due to non-inactivating mutations 
in the gene that reduce the activity of the enzyme (Arias, 1962). Studies 
in CNSII patients with mild hyperbilirubinemia showed that their bile 
contains mostly unconjugated bilirubin, monoglucuronides and a small 
fraction of diglucuronides (Sinaasappel and Jansen, 1991). 
Phenobarbitol-induced UGT1A1 expression is sufficient to prevent 
bilirubin-induced encephalopathy, by reducing the levels of plasma 
bilirubin (Yaffe et al., 1966). 
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Gilbert syndrome 
Gilbert syndrome affects 3-13% of the populations (Owens and Evans, 
1975; Travan et al., 2014). It is the mildest form of genetic 
hyperbilirubinemia with at least 50% reduction in hepatic biliubin 
UGT1A1 enzyme activity (Auclair et al., 1976). The most common 
genotype in the Caucasian population is the presence of two extra TA 
bases in TATAA box in the promoter region of UGT1A1 gene. The 
presence of the extra TA dinucleotide in the promoter region decreases 
the RNA polymerase affinity to promoter, which leads to reduced gene 
expression (Bosma et al., 1995; Monaghan et al., 1996). Other genetic 
conditions include blood related disorders like ABO incompatibility and 
Glucose-6 phosphate dehydrogenase deficiency. These conditions 
aggravate the hyperbilirubinemia by increased hemolysis and altered 
metabolism (Kaplan et al., 2000; Kaplan et al., 1997). 
 
1.2.2 Non-genetic hyperbilirubinemia 
The most common cause of non-genetic hyperbilirubinemia is the 
delayed induction of the UGT1A1 enzyme after birth, which is more 
pronounced in pre-term babies. Hyperbilirubinemia may be further 
aggravated by other conditions, such as increased breakdown of fetal 
erythrocytes, inefficient transport of serum albumin to liver, leading to 
acute bilirubin encephalopathy (Bhutani and Wong, 2013; Greco et al., 
2016). 
Several non-genetic factors can also affect bilirubin metabolism. 
Pathological conditions like sepsis, viral infection, hypoxia, or hepatic 
disorders may affect liver function by impairing the glucuronidation 
system and, thereby, increasing serum unconjugated bilirubin levels. 
Another possible cause of hyperbilirubinemia is related to breast milk 
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feeding. Breast milk reduces the expression of the intestinal UGT1A1, 
thus contributing to the elevated level of UCB during early neonatal 
days when the expression of liver enzyme is very low (Fujiwara et al., 
2012). Neonatal jaundice may be further complicated by the β-
glucuronidase enzyme of breast milk, due to increased bilirubin de-
conjugation and reabsorption in the gut. In addition, inadequate breast 
milk consumption may result in dehydration, further complicating the 
condition of the newborn. 
 
1.3 Free bilirubin (Bf) concept 
Most clinical laboratories biochemically measures total serum bilirubin 
(TSB) into direct and indirect fraction. The direct fraction consists of 
bilirubin mono and di-glucuronides, while indirect bilirubin (UCB) is 
made up of the fraction left after subtraction of direct bilirubin from 
total bilirubin (Smith et al.). 
Bilirubin has poorly aqueous solubility at physiological pH and needs to 
enter the liver in order to get conjugated by the UGT1A1 enzyme in 
hepatocytes. Due to its high binding affinity to serum albumin, bilirubin 
travels in the bloodstream bound to albumin (Ostrow et al., 1994). As 
the level of TB increases, the bilirubin-binding capacity of serum 
albumin gets saturated resulting in the increase in the UCB free fraction 
(Bf), which is not bound to albumin (Wennberg et al., 1979). Bf is 
usually less than 0.1% of the total plasma bilirubin. Due to its lipophilic 
nature, this small fraction of total bilirubin (Bf) can cross lipid-rich 
membranes. This is particularly important in hyperbilirubinemic 
conditions, as Bf may cross the blood-brain-barrier (BBB), 
accumulating in specific brain regions, causing severe neurotoxicity 
and, eventually, permanent brain damage (Ostrow et al., 2004). Bf is the 
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main player in bilirubin-induced encephalopathy in jaundiced newborns 
and patients with Crigler-Najjar syndrome Type I and II (Ahlfors and 
Wennberg, 2004; Ihara et al., 1999; Wennberg et al., 2006). Studies in 
hyperbilirubinemic animals showed Bf to be a major determinant of 
bilirubin-induced toxicity (Wennberg and Hance, 1986). In premature 
neonates with hyperbilirubinemia induced encepthalopathy, Bf is a more 
sensitive marker than TB (Amin et al., 2001). Recently, our lab showed 
that administration of human serum albumin to a genetic mouse model 
of neonatal hyperbilirubinemia resulted in increased plasma serum 
bilirubin binding capacity, leading to the mobilisation of bilirubin from 
tissues to plasma (Vodret et al., 2015). This resulted in the reduction of 
plasma Bf, forebrain and cerebellum bilirubin levels, saving the life of 
the hyperbilirubinemic pups. Unfortunately, free bilirubin is not 
measured regularly in jaundiced patients due to unavailability of 
sensitive and accurate measurement methods (Ahlfors et al., 2006; Amin 
and Lamola, 2011). 
 
1.4 Bilirubin-induced neurological dysfunction (BIND) 
Neonatal hyperbilirubinemia and jaundice affects about 85% of the 
newborns. It is usually a benign and transitional condition for the 
majority of neonates. However, increased levels of UCB may cause 
serious brain damage to a small proportion of newborns when mild 
bilirubin encephalopathy is followed by acute bilirubin encephalopathy 
(kernicterus) (Watchko and Tiribelli, 2013). In recent years, the interest 
in bilirubin-induced encephalopathy reawakened due to increase in its 
prevalence, associated to reduced monitoring consequent to early 
discharge of mothers and neonates from the hospitals (Bhutani and 
Wong, 2013; Kaplan and Hammerman, 2005). Newborns with 
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prolonged bilirubin exposure experience clinical symptoms like 
lethargy, opthalmoplegia (ocular muscles paralysis), high pitch crying, 
opisthotonus (bowed body and rigid extremities or dystonia), and 
seizures, as well as mental retardation, and often death by kernicterus 
(Shapiro, 2003; Smitherman et al., 2006). The regions targeted by 
bilirubin in developing brain includes basal ganglia, cochlear and 
occulomotor nuclei, cerebellum that includes granular and Purkinje 
neurons (Lauer and Spector, 2011; Watchko, 2006). Even moderate 
levels of UCB have been associated with developmental delay, 
attention-deficit disorders, autism, and isolated neural hearing loss 
(Shapiro, 2010). Exposure to high levels of bilirubin for long time may 
lead to severe neurological sequelae and it could have permanent impact 
on infant’s learning and memory. 
Severity of BIND can be measured by magnetic resonance (Refaey et 
al., 2017), images of brain (Shah et al., 2003), or by brain auditory 
evoked potential (BAEPs, or auditory brainstem response ABRs), as the 
auditory system is particularly sensitive to bilirubin toxicity (Shapiro 
and Nakamura, 2001). Hence, response to auditory stimuli represents a 
reliable method to investigate the neuronal activity. 
So, detailed identification of different neurological events and new 
molecular targets triggering bilirubin toxicity will help to better 
understand and management of BIND. 
 
1.5 Kernicterus 
‘Kernicterus’ is defined as the condition of irreversible brain damage 
produced by prolonged exposure to bilirubin. This term was coined by 
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Christian Schmorl in 1903 which means “yellow kern”, kern represents 
the most severely affected part of brain .i.e. nuclear region. 
The incidence of kernicterus is variable in different parts of world, with 
10 per 100,000 live births in the western world, while in low-income 
and middle-income countries it rises up to73 per 100,000 live births 
(Bhutani and Wong, 2013; Greco et al., 2016). Death due to kernicterus 
in Africa is ranked amongst the top 3 causes of death in newborns 
(Olusanya et al., 2014). The incidence rise in preterm infants born 
before 30 weeks of gestation (1.8 per 1000 live births) (Morioka et al., 
2015). Increased incidence of kernicterus in America and rest of the 
world during 1980s and 1990s has been linked to early hospital 
discharge, the influence of managed care, increase in number of breast 
feeding infants and inappropriate breastfeeding during first week of life 
(Moerschel et al., 2008). 
 
1.6 Mechanisms of bilirubin toxicity 
 
1.6.1 Neurodegeneration 
Neurodegeneration is the term used to describe the progressive loss of 
neuronal structure and function, including the death of neurons. Since 
neurons are post mitotic in nature, neurodegeneration strongly affects 
the central nervous system (CNS). Most of the attention, nowadays, is 
focussed on neurodegenerative diseases like Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington disease (HD) and Amylotrophic 
lateral sclerosis (ALS) (Brettschneider et al., 2015). In humans, most of 
the clinical and physiological features overlap between different 
neurodegenerative diseases, leading to misdiagnosis of the disease, 
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neurodegeneration being the shared feature. To avoid the problems with 
the phenotypic mis-identification of neurodegenerative diseases, animal 
models serve as useful tools to better characterize neurodegeneration 
(Harvey et al., 2011). Despite many efforts, the causes and key 
mechanisms initiating neurodegeneration are not yet well understood. 
Neurodegenerative diseases are not merely characterised by altered 
neuronal function. They are also caused by events that can affect the 
integrity of neurons and development, such as lack of oxygen, leading to 
loss of dendrites and extensive fragmentation of the dendritic arbour 
(Wen et al., 2013), and traumatic brain injury (Petzold et al., 2011), 
resulting in neuronal cell death. 
Neurodegeneration can be also caused by severe hyperbilirubinemia. 
Although neonatal jaundice is a benign and transient form of 
hyperbilirubinemia, bilirubin may raise up to neurotoxic levels. High 
lipid content of neuronal cells makes them particularly vulnerable to 
bilirubin due to high affinity of bilirubin to lipid rich membranes, 
especially myelin-rich membranes (Watchko and Tiribelli, 2013). UCB 
treatment reduced viability of dividing neuronal precursor cells, while 
neurogenesis is reduced without affecting astrogliogenesis (Fernandes et 
al., 2009). Differentiating hippocampal cells showed reduced neuronal 
arborization, dendritic output and axonal arborization after exposure to 
bilirubin (Fernandes et al., 2009). Bilirubin treatment inhibits 
cytochrome c activity in immature neuronal cells. In addition, bilirubin 
treatment impairs cellular oxygen consumption and collapses 
mitochondrial membrane potential that leads to apoptosis of neuronal 
cells (Vaz et al., 2010). Another report showed that exposure of primary 
rat neurons to bilirubin dissipates the mitochondrial membrane potential, 
leading to cellular energy failure followed by cytochrome c release and 
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activation of caspases and programmed cell death (Rodrigues et al., 
2000). Bilirubin decreases cell viability by altering the redox status of 
cells (Tell and Gustincich, 2009). In vivo studies showed extensive 
Purkinje cells (PCs) degeneration in mouse models of 
hyperbilirubinemia (Barateiro et al., 2012; Bortolussi et al., 2014a; 
Bortolussi et al., 2012). In Gunn rats, acute hyperbilirubinemia leads to 
the impairment of presynapsis of glutaminergic neurons (Haustein et al., 
2010). 
 
1.6.2 Oxidative stress 
Oxidative stress is the term used to define the state where imbalance of 
the antioxidant system occurs, with excessive incorporation/over 
production of free radicals/reactive oxygen species (ROS) from 
environment to the living system. Although oxygen is very important for 
life, impaired oxygen metabolism and ROS over-production is involved 
in several neurodegenerative diseases like AD, PD, and others (Uttara et 
al., 2009). Free radicals are chemical entities with unpaired electrons 
(McCord, 2000). They can be the by-product of aerobic respiration, by-
products released from chemical reactions, or generated from 
electromagnetic radiations. The presence of unpaired electrons makes 
them extremely unstable, which in turn, become stable after transferring 
the unpaired electron to other molecules. However, these free radicals 
may be detrimental to cells due to their ability to oxidise proteins, DNA 
and lipid molecules of the cells. The levels of free radicals are tightly 
regulated by the cellular machinery. To overcome the detrimental effect 
of free radicals, cells have several enzymes involved in the antioxidant 
response like superoxide dismutase, glutathione peroxidase, catalase, 
thioredoxin, glutathione transferases, and HO1 (Cho et al., 2002). In 
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addition to enzymes of antioxidant system, non-enzymatic anti-oxidant 
molecules like β-carotene, vitamin C and E, uric acid and glutathione 
also helps to scavenge the free radicals (Birben et al., 2012). 
One of the most extensively studied gene of the antioxidant system is 
the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) (Jung et al., 2017). 
Oxidative stress leads to the transport of Nrf2 from cytoplasm to 
nucleus, where it binds to the antioxidant response element (ARE) in the 
upstream region of genes of the antioxidant system, such as glutathione 
transferases, oxidoreductases and HO-1 (Nguyen et al., 2009; Nguyen et 
al., 2003). HO-1, being an enzyme of antioxidant system, also plays an 
important role in bilirubin catabolism. 
Mildly elevated concentrations of bilirubin are considered beneficial due 
to its antioxidant property (Stocker et al., 1987). Neonates having 
physiological jaundice  have lower oxidative stress compared to controls 
(Kumar et al., 2007). However, higher concentrations of bilirubin lead 
to oxidative stress. Oxidative stress has been shown to play an important 
role in bilirubin neurotoxicity in vitro, through the increase in the level 
of glutathione in cells (Giraudi et al., 2011). Treatment of synaptosomal 
vesicles from gerbil cortical brain tissue with bilirubin leads to oxidative 
stress, loss of membrane asymmetry and functionality, lipid and protein 
oxidation and calcium intrusion (Brito et al., 2004). Treatment of Hepa 
1c1c7 cells with bilirubin leads to oxidative stress, loss of mitochondrial 
membrane potential and caspase9 activation (Oakes and Bend, 2005; 
Seubert et al., 2002). In vitro experiments with HeLa cells and mouse 
embryonic fibroblasts (MEFs) showed bilirubin-induced oxidative stress 
after treatment with 80nM Bf (Cesaratto et al., 2007). Treatment with 
bilirubin creates ROS in SH SY 5Y cells and results in the 
overexpression of DJ-1 protein, a protein involved in various cellular 
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processes including oxidative stress (Deganuto et al., 2010). 
Sulphadimethoxine-induced hyperbilirubinemia in pups of Gunn rats 
causes lipid peroxidation, as determined by the levels of 4-hydroxy-2-
nonenal (Bortolussi et al., 2015; Daood et al., 2012).UCB treatment 
leads to oxidative stress and apoptosis of neurones and astrocytes (Brito 
et al., 2008a; Brito et al., 2008b; Silva et al., 2001; Vaz et al., 2011). 
Similarly, bilirubin induces oxidative stress in SH SY 5Y and immature 
cortical neuronal cells (Qaisiya et al., 2014; Vaz et al., 2010). Research 
from our group has shown bilirubin-induced disturbance in the 
antioxidant system in the cerebellum of the C57BL/6 Ugt1-/- mouse 
model. 2D-gel electrophoresis and expression analysis of the cerebellum 
revealed increased expression of Nrf2 and lower expression of SOD1 
(Bortolussi et al., 2015). Another interesting result includes the 
increased oxidation of peroxidase 2 and 6 upon bilirubin exposure. The 
perturbation in the antioxidant machinery of neuronal cells leads to their 
death (Bortolussi et al., 2015). Bilirubin induced oxidative stress was 
shown in another mouse model of hyperbilirubinemia. They observed an 
increase in oxidised glutathione and HO-1 protein levels in these 
animals (Yueh et al., 2014). 
 
1.6.3 Endoplasmic reticulum stress 
The endoplasmic reticulum (ER) is a specialized organelle of cells that 
contains several chaperones and detectors to facilitate protein folding 
and to detect the presence of misfolded/unfolded proteins, respectively. 
The ER has a strong oxidising environment to form disulfide bonds, and 
it may acts as a source of free radicals, suggesting a strong link between 
ER and oxidative stress (Malhotra and Kaufman, 2007). Depending on 
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the type of stress, ER stress response can be activated by one of the 
following proteins/pathways, or by their combination (Figure 3). 
a) Inositol requiring 1 (IRE1). 
b) Protein kinase RNA – like endoplasmic reticulum kinase (PERK). 
c) Activating transcription factor 6 (ATF6).  
Each of the above-mentioned proteins makes a different signalling 
network, which gets activated depending upon the type of stress (Doyle 
et al., 2011). The activation of unfolded protein response delays the 
translation process in order to clear the unfolded proteins and induces 
the expression of proteins involved in cell survival and protein 
degradation.  
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Figure 3. Endoplasmic reticulum stress signalling. ER stress activates three 
different master regulators (IRE1, PERK and ATF6) of ER stress in response to the 
accumulation of unfolded proteins. All three tranducers activate downstream targets 
that alleviate ER stress (Fonseca et al., 2011). 
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The accumulation of unfolded proteins stimulates ER stress, 
consequently the ER chaperone glucose-regulated protein 78 (GRP78) 
gets separated from IRE1, PERK and ATF6 (Doyle et al., 2011). GRP78 
also helps newly synthesized proteins to get folded correctly. 
Generally, the main role of this pathway is to restore the normal 
function of the cells by the activation of UPR target genes. However, if 
the ER stress sustains for longer time, then cells cannot attain the steady 
state. In this case, accumulation of unfolded proteins ends up with the 
activation of the apoptotic pathway. Activation of the C/EBP 
homologous protein (CHOP) and CD95/Fas leads to apoptosis by 
activating caspases (Li et al., 2014; Peter et al., 2015). In cancer cell 
lines, activation of ER stress leads to the increased transcription of 
important regulators like death receptor 5 (DR5), activating transcription 
factors 3 (ATF3) and 4 (ATF4), and CHOP. The activation of these 
genes results in apoptosis induced by the upregulation of caspase 9, 
caspase 8 and caspase 3 (Liu et al., 2012). ER stress is one of the main 
contributors to neurodegenerative diseases. Infact, neurodegenerative 
diseases like HD, AD, PD, and ALS are characterised by accumulation 
of aggregated proteins that affect ER stability. 
ER homeostasis is also impaired by treatment of cells with bilirubin. 
Treatment of oligodendrocytes with bilirubin leads to the activation of 
ER stress by the overexpression of GRP78, IRE1 and ATF6 (Barateiro 
et al., 2012). Trancriptomic analysis of neuroblastoma cells after 
bilirubin treatment showed upregulation of ER stress-related genes such 
as CHOP and ATF3 (Calligaris et al., 2009). Another study showed 
ATF6, CHOP and GRP78 upregulation at mRNA level by bilirubin 
treatment of neuroblastoma cells. GRP78 was upregulated at protein 
level in neuroblastoma cells after bilirubin treatment; while ATF6 was 
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not upregulated at protein level. ER stress inhibition increases the 
survival of neuronal cells suggesting ER stress as one of the mechanism 
responsible for neurotoxicity (Qaisiya et al., 2017a). In vivo studies from 
our lab showed the upregulation of ATF3, CD95/Fas and CHOP, with 
the highest expression at the most aggressive stage of bilirubin toxicity. 
Immunofluorescence analysis of brain sections of hyperbilirubinemic 
mutant mice during early stages showed increased levels of CHOP in all 
the layers of the cerebellum. During later stages, CHOP and CD95/Fas 
was localised mostly in Purkinje cells. CHOP was localised mostly in 
severely degenerating Purkinje cells that were surrounded by microglia 
cells, suggesting microglia activation (Vodret et al., 2017). Microarray 
analysis of hepatoma cells treated with bilirubin showed the activation 
of ER stress, as revealed by overexpression of GRP78, ATF3, CHOP 
and PERK activation by phosphorylation (Oakes and Bend, 2010). 
 
1.6.4 Neuroinflammation 
Neuroinflammation is the general term used to describe inflammation in 
the brain and spinal cord. The CNS immune surveillance is mainly 
provided by glia (microglia, astrocytes, macrophages and 
oligodendrocytes) and endothelial cells. CNS inflammation normally 
acts as a protective mechanism of neuronal cells from stress. However, 
prolonged activation of inflammatory response may further result in the 
damage of neurons by the activation of glial cells. Migrating 
microglial/macrophages cells can either repair or exacerbate the 
situation, depending on their activation status. The ratio between M1 
and M2 microglia cells determine the response, whether pro-
inflammatory or anti-inflammatory. M1 microglia is pro-inflammatory 
and is associated with clearance of dead tissues (Kigerl et al., 2009; 
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Martinez et al., 2006), whilst M2 microglia is anti-inflammatory and are 
involved in repair of injured tissues by reducing the inflammatory 
mediators (Kigerl et al., 2009; Martinez et al., 2006). 
Neurodegeneration is a common feature of several neurodegenerative 
diseases (Frank-Cannon et al., 2009). Activated microglia cells and their 
relative inflammatory markers accumulate at the site of 
neurodegeneration. Studies have been performed to verify the effect of 
bilirubin on the activation of glia cells. Bilirubin exposure activate 
astrocytes (Falcao et al., 2007; Fernandes et al., 2007; Fernandes et al., 
2006; Fernandes et al., 2004) and microglia, resulting in the release of 
IL1β, IL6, TNFα, NFKβ, interferon γ (INFγ), and glutamate (Fernandes 
and Brites, 2009; Gordo et al., 2006; Silva et al., 2010). Activated 
microglia and astrocytes are also present in the brain of Gunn rats 
(Liaury et al., 2012; Mikoshiba et al., 1980). Activated glia cells are also 
found in a Ugt1a1 knockout mouse model (Barateiro et al., 2016; Vodret 
et al., 2017; Yueh et al., 2014). Bilirubin treatment leads to the 
expression of neuroinflammatory cytokines like IL-8, TNFα and NFкB 
in neuroblastoma cells (Qaisiya et al., 2017a). In vivo study in mutant 
animals found activation of microglia and astrocytes in cerebellum. 
Inflammatory regulators and TNFα were upregulated in mutant animals 
during most aggressive stage of bilirubin toxicity at mRNA level. 
Immunofluorescent analysis in cerebellum from mutant animals showed 
expression of TNFα in both astrocytes and microglia during the most 
severe stage of bilirubin toxicity. More detailed analysis into the type of 
microglia activated during neuroinflammation revealed activation of 
pro-inflammatory M1 microglia with a parallel decrease in anti-
inflammatory M2 type microglia (Vodret et al., 2017). 
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1.6.5 Autophagy 
Autophagy is a process of self degradation of a portion of the 
cytoplasm by the lysosome. During starvation, cells activate autophagy 
to increase the supply of nutrients to cells (Kuma et al., 2004). Basal 
autophagic activity is normally considered as a pro-survival 
mechanism, protecting cells from different types of stress (Scott et al., 
2007). Autophagy is dysregulated in several neurodegenerative 
diseases like spinocerebellar ataxia (SCA), PD and HD (Calligaris et 
al., 2009; Rubinsztein et al., 2005). 
In vitro experiments showed autophagy activation in cells by bilirubin 
treatment. Bilirubin-treated neuroblastoma cells overexpress the 
regulators of autophagy such as GABARAPL1 (GABA (A) or ATG8), 
and WIPI1 (WD repeat domain, phosphoinositide interacting 1 gene or 
Atg18) (Calligaris et al., 2009). Brain microvascular endothelial cells 
(BMEC) overexpress LC3 after exposure to bilirubin (Palmela et al., 
2012). In vitro experiments in SH SY 5Y cells showed autophagy 
activation after bilirubin treatment (Qaisiya et al., 2017b). 
Hyperbilirubinemic mutant mice have activation of autophagy during 
the most aggressive stages of bilirubin toxicity suggesting autophagy 
may be a pro-survival mechanism used by cells against bilirubin-
induced stress (Vodret et al., 2017).  
 
1.6.6 DNA damage 
As already mentioned above (Section 1.6.2), bilirubin can induce 
oxidative stress. Higher rate of oxidative metabolism in the brain 
accompanied by lower expression of antioxidant enzymes in neurons, 
compared to other somatic tissues, make them extremely susceptible to 
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oxidative stress. As a result, numerous oxidative lesions may 
accumulate in neurons due to the above-mentioned factors (Brooks, 
2000). Association between oxidative stress and markers of oxidative 
stress have been already proven. In addition, DNA damage has been 
found to be an important factor to initiate neuronal cell death in several 
neuropathological diseases (Gabbita et al., 1998; Mattson, 2000). A 
previous study showed increased levels of 8-OH G (marker of DNA 
damage) in neonates even with lower bilirubin concentration (Basu et 
al., 2014). Bilirubin exposure results in DNA strand breaks in 
lymphocytes (Khan and Poduval, 2012). Bilirubin also induces double 
stranded breaks (DSBs) in the presence of Cu (Frock et al.) ions due to 
the generation of reactive oxygen species (ROS) (Asad et al., 1999). 
Treatment of SH SY 5Y cells with bilirubin leads to DNA damage and 
reduction in growth of cells. Levels of 8-OH G were upregulated after 
bilirubin treatment (Deganuto et al., 2010). 
 
1.7 DNA damage in neurodegenerative diseases 
Accumulation of DNA damage in neurons is a common feature of 
neurodegenerative diseases that includes ataxias, AD, PD, and HD 
(Kulkarni and Wilson, 2008; Rass et al., 2007). Higher rate of 
mitochondrial and nuclear DNA damage is attributed to the higher rate 
of mitochondrial respiration and ROS production (Weissman et al., 
2007). Defects in base excision repair (BER) and single stranded break 
repair (SSBR) pathways trigger neuronal dysfunction and degeneration 
(Caldecott, 2008; Rass et al., 2007).  The limited capacity of neurons of 
being replaced during adult stages and the accumulation of damaged, 
but irreplaceable, terminally differentiated neurons make them 
particularly vulnerable to DNA damage. In addition, neuronal cells 
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being in the G0 phase of the cell cycle utilize mostly the error-prone 
NHEJ to repair DNA damage (Rass et al., 2007). Neurons are highly 
transcriptionally active and oxidative stress can block transcription. This 
leads to shortage of transcripts in neuronal cells in normal ageing 
individuals that result in degeneration and apoptosis of neuronal cells 
(Ljungman and Lane, 2004). 
 
1.8 DNA damage response 
The main objective of every life form is to duplicate the genetic material 
followed by its transmission to the next generation with extreme fidelity. 
Duplication of genetic material should be done precisely, despite being 
exposed continuously to several exogenous and endogenous DNA 
damaging agents. To overcome the damaging effects of these agents, 
cells have developed different signalling mechanisms to recognise DNA 
damage, signal its presence, followed by repair of the damage. Cells 
having defects in these mechanisms are extremely sensitive to many 
types of DNA damaging reagents (Jackson and Bartek, 2009). DNA can 
be damaged by mis-incorporation of bases during the normal replication 
of the cells. DNA strand breaks can also be generated by aborted 
topoisomerase I and II activity. DNA can be damaged by reactive 
oxygen species (ROS) generated as by-products of the oxidative 
metabolism. ROS can be also generated by several environmental 
toxins, as well as by heavy metal-mediated Fenton reaction (Valko et 
al., 2006). ROS and reactive nitrogen species (Bernstein and Landing) 
can also be generated by neutrophils and macrophages during 
inflammation and infections (Kawanishi and Hiraku, 2006). These 
species can attack the DNA, leading to the formation of DNA adducts. 
These modified bases can impair base pairing, block DNA replication 
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and transcription, resulting in the loss of bases followed by single 
stranded breaks (SSBs) formation. DSBs can be generated when two 
SSBs are present in immediate proximity or when the DNA replication 
apparatus meets these SSBs or any other type of DNA lesion. Although 
DSBs are not so frequent like other lesions listed above, they are 
extremely deleterious to cells (Khanna and Jackson, 2001). 
To counteract against the deleterious effect of DNA damage, cells have 
evolved distinct mechanism to detect the DNA damage, signal their 
presence and finally promote their repair (Harper and Elledge, 2007; 
Harrison and Haber, 2006). 
 
1.9 DNA repair pathways 
The diversity of DNA damaging lesions makes compulsory for cells to 
have multiple DNA repair pathways (Figure 4). Some lesions get 
repaired simply by a series of catalytic events catalyzed by a set of 
multiple proteins. During mismatch repair (MMR), mismatches, 
insertions/deletions loops lead to single stranded breakage that get 
finally repaired with the participation of polymerases, nucleases and 
ligases (Jiricny, 2006). In the case of the base-excision repair (BER) 
pathway, detection of mismatches and insertion/deletions loops by DNA 
glycosylase removes the damaged base before getting repaired by 
nucleases, polymerases and ligases (David et al., 2007). The nucleotide-
excision repair pathway (NER) system recognises lesions that distort the 
DNA helix. NER operates by two different sub-pathways: transcription-
coupled NER and global NER. Transcription-coupled  NER repairs 
DNA lesions that block transcription, while global NER focuses on the 
helix distorting lesions that spread over the whole genome 
(Hoeijmakers, 2001). 
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The DSB repair pathway includes Non-Homologous End Joining 
(NHEJ) pathway (Lieber, 2008; Shibata, 2017) and Homologous 
Recombination (HR) (San Filippo et al., 2008). The NHEJ gets activated 
after DSB ends recognition by the Ku protein followed by binding and 
activation of the protein kinase DNA-PKcs. DNA PKcs activation leads 
to the recruitment and activation of end-processing enzymes, 
polymerases and DNA ligase IV (Baumann and West, 1998). Non-
canonical Ku-independent NHEJ pathways includes micro homology 
mediated end joining (MMEJ) or alternative end joining (Alt- EJ). 
Activation of these Ku-independent pathways always results in deletions 
(Boulton and Jackson, 1996; Liang et al., 1996; McVey and Lee, 2008). 
Despite being error prone, NHEJ and Alt-EJ occurs in all phases of cell 
cycle. In contrast, HR can occur only during the S and G2 phases of the 
cell cycle due to the requirement of template strand to repair the damage 
precisely (San Filippo et al., 2008). The HR pathway is initiated by 
ssDNA formation. ssDNA formation is catalyzed by Mre11-Rad50-
NBS1 (MRN) complex. In the next step, ssDNA invade the intact 
template strand, process which is catalyzed by Rad51, Brca1 and Brca2 
proteins. After strand exchange, substrate resolution occurs with the 
help of polymerases, helicases and ligases (Figure 4) (Jackson and 
Bartek, 2009).  
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Figure 4. Different DNA repair pathways. DR: represents direct enzymatic repair, 
MGMT- O6-alkylguanine-DNA-alkyltrasferase, BER-Base excision repair, NER-
nucleotide excision repair, GGR-Global genome repair, TCR-Transcription coupled 
repair, MMR-Mis-match repair, DSBR-Double stranded break repair, HR-
Homologous Recombination, NHEJ-Non-Homologous End Joining. Adapted from 
(Damia and D'Incalci, 2007). 
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1.9.1 DNA damage and cell cycle checkpoints 
The two most important DNA damage response (DDR) sensor protein 
kinases present in cells are Ataxia Telangiectasia mutated (ATM) and 
Ataxia Telangiectasia and Rad-3 related(ATR). ATM gets activated by 
double stranded breaks while ATR gets activated by Replication protein 
A (RPA) coated-ssDNA (Bartek and Lukas, 2007; Cimprich and Cortez, 
2008; Shiloh, 2003). After recognition of DNA damage, ATM and ATR 
signal further downstream to activate CHK2 and CHK1 respectively. 
CHK1 and CHK2, along with ATM and ATR function to reduce the 
activity of cyclin dependent kinases (CDKs), by different mechanisms, 
activation of P53 is the most common one (Bartek and Lukas, 2007; 
Kastan and Bartek, 2004; Riley et al., 2008). Inhibition of CDKs leads 
to the slowing down or arrest of cell cycle at G1/S, intra S and G2/M 
checkpoint, giving time to the cell to repair the DNA before replication 
and mitosis initiates. 
 
1.9.2 Homologous Recombination 
The HR pathway plays an important role in the repair of DNA double 
stranded breaks. It uses the intact homologous sequence as template for 
repair (Heyer et al., 2010) (Figure 5). The repair process of the damaged 
piece of DNA requires the close proximity between undamaged 
homologous sequence and the damaged DNA sequence during S and G2 
phases of cell cycle (Renkawitz et al., 2014; Weiner et al., 2009). HR 
can be divided into three substages: pre-synaptic, synaptic and post-
synaptic phases.  
The pre-synaptic phase is initiated by the binding of Mre11-Rad50-Xrs2 
(MRX) complex in S cerevisae and Mre11-Rad50-Nbs1 (MRN) 
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complex in humans to the broken DNA termini (Lee et al., 2003; Paull 
and Gellert, 1999; Stracker and Petrini, 2011; Trujillo et al., 2003). In 
the next step, Mre11 together with CtIP initiates the 5’-3’ resection at 
the broken DNA ends (Sartori et al., 2007; Symington and Gautier, 
2011; Williams et al., 2007). The resection step is further continued by 
the concerted action of Exo1 (exonuclease 1), and the helicase-
endonuclease activity of the Sgs-Top3-Rmi1 (STR)-Dna2 complex 
(BLM-TopoIIIα-RMI1/RMI2 (BTR)-DNA2 complex 1 (Cejka et al., 
2010; Niu et al., 2010; Symington and Gautier, 2011). After end 
resection, the ssDNA binding protein Replication protein A (RPA) coats 
the ssDNA to minimize the secondary structure formation facilitating 
Rad51 loading. Rad51 binding to ssDNA leads to the formation of a 
presynaptic nucleoprotein, which can pair with the intact strand of sister 
chromatid after homologous sequence has been found during homology 
search (Fanning et al., 2006; Heyer et al., 2010).  
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Figure 5. The Homologous Recombination pathway. Homologous 
Recombination pathway is divided into presynaptic (includes 5’-3’ end resection, 
Rad51 filament formation and homology search), synaptic (this phase is 
characterised by D-loop formation) and post-synaptic phases resulting in different 
types of recombination products (this phase includes all steps after D-loop 
formation). Adapted from (Renkawitz et al., 2014). 
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Next is the synaptic phase, which is characterised by DNA strand 
exchange between the target DNA and Rad51 nucleofilament to form a 
structure known as displacement loop (D-loop). The D-loop consists of 
the heteroduplex DNA and the displaced strand of the donor DNA 
(Heyer et al., 2010; Shinohara et al., 1992). The next step is the post- 
synaptic phase, in which DNA synthesis starts at the 3’ end of broken 
ends. During classic DSB repair pathways, the second end of the DSB 
aligns with the D-loop to form a double holiday junction (Ferguson and 
Holloman, 1996; Heyer et al., 2010; Nassif et al., 1994). In the next 
phase, resolvases such as Yen1 (GEN1) or the Mus8-Mms4 complex 
(MUS81-EME1) can either generate a crossover product or a non-
crossover product from these symmetrical structures (Figure 5) (Heyer 
et al., 2010). 
 
1.9.3 Homologous recombination reporter cell line (HeLa DR-
GFP) 
A very useful tool for the study of homologous recombination is the 
HeLa DR-GFP stable cell line. It contains a single integration site of a 
reporter construct, which has two differentially inactivated versions of 
tandemly repeated (DR) GFP, developed by Maria Jasin (Pierce et al., 
1999). The upstream GFP gene (Cassette I) is interrupted by a Isce1 
restriction enzyme site, a rare-cutting endonuclease (Jasin, 1996). 
Introduction of the Isce1 site leads to the formation of two in frame stop 
codons in Casette I, thereby inactivating Casette I. The downstream 
GFP fragment (Casette II) is truncated at 5’ and 3’ ends, resulting in a 
truncated, inactive, GFP product (502 bp).  
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Figure 6. HeLa DR-GFP cell line. The HeLa DR-GFP cell line is a stable clone 
containing a single insertion of a recombination-reporter cassette. It is composed by 
an upstream GFP fragment interrupted by Isce1 site that leads to the introduction of 
two STOP codons. Downstream of the Isce1 GFP fragment, the t-GFP fragment is 
present, with both the 5’ and 3’ termini truncated. Transfection of the cells with 
plasmid encoding Isce1 leads to the Homologous Recombination between two 
fragments that lead to GFP expression. Adapted from (Cuozzo et al., 2007). 
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Transient transfection of cells with a plasmid encoding Isce1 induces 
Homologous Recombination between the two cassettes and production 
of active GFP, that can be quantified by flow cytometry (Figure 6) 
(Cuozzo et al., 2007). 
 
1.9.4 Non- Homologous End Joining (NHEJ) 
NHEJ is one of main DSB repair pathway of cells. It involves the re-
ligation of the broken ends of the DNA (Weterings and Chen, 2008). 
NHEJ can mediate the ligation of any type of DNA ends. However, in 
contrast to HR, NHEJ does not require a homologous template to repair 
the DNA damage. Since NHEJ does not require a template, it is not 
restricted to a particular cell cycle phase. 
The NHEJ can be divided into four sequential steps: 1) DNA end 
recognition by Ku heterodimer. The Ku heterodimer is composed of 
Ku70 and Ku80 at the DNA breakage site. The Ku heterodimer then acts 
as a scaffold for the recruitment of other NHEJ proteins. The Ku 
heterodimer has been shown to recruit directly and indirectly different 
NHEJ factors to DSBs like DNA-PKcs (Uematsu et al., 2007), X-ray 
cross complementing protein-4 (Xrcc4) (Costantini et al., 2007; Mari et 
al., 2006; Nick McElhinny et al., 2000), Xrcc4 like factor (XLF) (Yano 
et al., 2008), Aprataxin-and-PNK-like factor (APLF) (Grundy et al., 
2013; Kanno et al., 2007; Macrae et al., 2008); 2) DNA end bridging 
and promotion of end stability. After DSB, Ku heterodimer binds to 
the broken DNA ends and maintains their stability because non-specific 
processing of DNA ends could lead to chromosomal aberrations and, 
thus, genomic instability. After recruitment of DNA-PKcs to DSBs 
ends, it forms a distinct structure at the broken DNA ends, which is 
likely to play an important role in the formation of the synaptic complex 
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that holds together the ends of the broken DNA ends (Cary et al., 1997). 
Other proteins include XRCC4 and XLF, that play an important role in 
stabilizing the broken DNA ends (Andres et al., 2012; Hammel et al., 
2011; Hammel et al., 2010; Malivert et al., 2010); 3) End processing. In 
this step, processing of DNA ends occurs to create DNA ends that can 
be ligated. Depending on the type of break, different end processing 
enzymes may be required. Different end-processing enzymes involved 
in NHEJ pathway include Artemis, PKNP, APLF, Polymerase µ and λ, 
Werner (WRN), aprataxin, and Ku. PNKP, Aprataxin and Ku are some 
of the factors that remove blocking end groups in order to make broken 
DNA ends accessible for ligation. DSBs can have non-ligatable 5’ 
hydroxyl and 3’ phosphate groups. PNKP is an enzyme that contains 
both kinase and phosphatase activity. The kinase domain of PNKP add 
phosphate group to the 5’ OH while phosphates domain removes 3’ 
phosphate group. Another protein is Aprataxin, histidine triad family 
member remove adenylate group covalently linked to 5’ phosphate 
termini (Ahel et al., 2006). Another research showed that Ku has 5’ 
deoxyribose-5-phosphate (5’-dRP)/AP lyase enzymatic activity (Roberts 
et al., 2010). Ku removes abasic sites near DSBs in vitro and this 
activity was highest when the abasic site was within a short 5’ overhang 
at DSB end. The proteins involved in resecting DNA ends in NHEJ are 
Artemis, WRN and APLF. Artemis has a number of nucleolytic 
activities, that includes 5’ endonuclease activity that nick a 5’ overhang 
and ultimately leaving blunt duplex, 5’-3’ exonuclease activity on 
single-stranded DNA and removal of 3’ phosphoglycolate group from 
the DNA termini (Ma et al., 2002; Povirk et al., 2007). DNA-
PKcs/ATM binding and phosphorylation activate Artemis. DNA-PKcs 
mediated phosphorylation of Artemis is required for its endonuclease 
activity (Ma et al., 2002). Another protein, Werner (WRN), interacts 
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with both the Ku heterodimer and XRCC4, and both proteins stimulate 
the 3’-5’ exonuclease but not the 3’-5’ helicase activity (Cooper et al., 
2000; Kusumoto et al., 2008; Perry et al., 2006). APLF activity on 
ssDNA or DNA overhangs is not modulated by another core NHEJ 
factors. APLF can resect 3’ overhangs in in vitro end joining assays to 
permit ligation of DNA ends by XRCC4- DNA ligase IV (Li et al., 
2011). Filing of gaps is performed by Family X polymerases which 
include DNA polymerases µ and λ in the presence of complex DNA 
damages (Moon et al., 2007). DNA polymerase µ is involved in 
template dependent synthesis in presence of dNTPs and rNTPs. DNA 
polymerase µ can polymerize across a discontinuous template strand in 
the presence of Ku, XRCC4/ DNA ligase IV (Nick McElhinny et al., 
2005). The activity of Polymerase λ is not dependent on template and 
lyase activity of Polymerase λ removes a damaged base (Ramadan et al., 
2004); 4) Ligation of broken ends and dissolution of NHEJ complex. 
In the final step, ligation of broken DNA ends by DNA ligase IV occurs. 
DNA ligase IV ligation activity is modulated by XRCC4. Adenylation 
of DNA ligase IV by XRCC4 stimulates its activity (Figure 7) 
(Grawunder et al., 1997). 
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Figure 7. Non Homologous End-Joining (NHEJ). NHEJ is divided into four 
sequential steps- 1) DNA end recognition. 2). DNA end bridging and promotion of 
end stability. 3). End processing. 4). Ligation of broken DNA ends and promotion of 
end stability. Adapted from (Davis and Chen, 2013). 
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1.9.5 NHEJ substrate vector (pIM EJ5-GFP) 
The pIM EJ5-GFP reporter cassette can detect multiple NHEJ events. It 
consists of a promoter which is separated from the GFP gene by a 
puromycin gene (Figure 8). The puromycin cassette is flanked by two 
Isce1 restriction enzyme sites that are present in the same orientation. 
After removal of the puromycin cassette by Isce1-induced DSB, 
formation of overhangs occurs followed by end-joining. This end-
joining process restores GFP expression by placing GFP cassette next to 
the promoter. An Isce1 resistant site could form during end-joining of 
overhangs due to error prone nature of the NHEJ pathway. However, 
NHEJ could reconstitute the Isce1 site without any error after end-
joining. In this case, the Isce1 site could be targeted again by Isce1 
enzyme that may form an Isce1 resistant site due to error prone 
mechanism of NHEJ (Figure 8). In any case, presence or absence of the 
Isce1 site after end joining does not affect the GFP expression 
(Bennardo et al., 2008). 
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Figure 8. pIM EJ5-GFP repoter plasmid. pIM EJ5-GFP plasmid consists of a 
promoter which is separated from GFP gene by puromycin gene. Puromycin gene is 
flanked by Isce1 site. GFP gene fragment placed downstream of the puromycin 
gene. Isce1 induced DSB leads to the joining of the GFP fragment with the promoter 
that leads to GFP expression. Adapted from (Bennardo et al., 2008). 
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1.10 Concept of genome editing 
The genome editing field had an exceptional development consequent to 
the development of site-specific nucleases that can be used, combined 
with the discovery that targeted DSBs could be used to activate the 
endogenous cellular DNA repair machinery. The DBSs in the genome 
can be repaired by one of the two pathways: Homologous recombination 
(HR) and Non-Homologous end joining (NHEJ) (Takata et al., 1998). 
Targeted double stranded break using site-specific nucleases can be used 
for gene knockout, gene knock-in and gene correction. 
 
1.10.1 Site-specific nucleases 
The successful implementation of site-specific genome editing relies on 
the introduction of targeted DSB in the genome using one of the 
following systems: meganucleases, transcription activator-like effector 
(TALE)-nucleases (TALENs), zinc-finger nucleases (ZFNs) and more 
recent one, CRISPR/Cas9 system. 
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Figure 9. Most commonly used site-specific nucleases used for genome 
editing (Maeder and Gersbach, 2016). 
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1.10.2 Meganucleases 
Meganuclease technology involves the re-engineering of the DNA 
binding specificity of homing endonucleases such as I-Cre1 and I-Sce1 
(Chevalier and Stoddard, 2001).  These homing endonucleases could be 
re-engineered to target novel sequences (Rosen et al., 2006; Smith et al., 
2006). Several studies showed the use of meganucleases in genome 
editing (Dupuy et al., 2013; Gurlevik et al., 2013). However, difficulty 
in separating the DNA binding and cleavage domain accompanied by 
the difficulty in engineering proteins with novel specificity limited the 
use of meganucleases. 
 
1.10.3 Zinc-finger nucleases (ZFNs) 
Zinc-finger (ZF) proteins are the most abundant class of transcription 
factors and the Cys2-His2 zinc-finger domain represents one of the most 
common DNA-binding domains encoded in the human genome (Tupler 
et al., 2001). Crystal structure of Zif268 suggests that zinc fingers form 
a compact ββα structure in the presence of zinc atom where the α-helical 
portion of each finger makes contact with 3 or 4 bp in the major groove 
of the DNA (Lee et al., 1989; Pavletich and Pabo, 1991). Tandem zinc 
finger motifs wrap around the DNA to recognize DNA sequences such 
that 3 finger modules/domains binds a 9 bp target site. The modular 
structure of Zif268 suggests its use as a probable framework for the 
engineering of novel DNA-binding motifs (Gersbach et al., 2014). The 
designing of Zinc fingers with unique specificity based on simple rules 
had some success during initial attempts (Desjarlais and Berg, 1992). 
Later on, combinatorial libraries combined with selection-based 
methods proved to be a more effective strategy to generate individual 
finger with novel DNA binding specificities (Rebar and Pabo, 1994); 
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(Choo and Klug, 1994). After initial success, designing of multi-finger 
arrays with novel target sites with unique specificity in a complex 
genome was a challenging task. This type of approach depends on the 
collections of single finger modules identified in naturally occurring 
proteins (Bae et al., 2003) or selected to bind specific 3 base pair target 
sites (Segal et al., 1999), which are then linked together in tandem to 
generate novel DNA binding proteins (Beerli et al., 2000). In another 
approach, known as OPEN, new proteins are selected from the random 
libraries (Maeder et al., 2008). Other approaches included those used by 
Sigma-Aldrich Compo Zr platform and Sangamo biosciences (Gupta et 
al., 2012; Sander et al., 2011b).  
The birth of zinc-finger nucleases (ZFN) technology was made possible 
by the observation that the DNA binding domain and the DNA cleavage 
domain of the Fok1 endonuclease can function independently from each 
other (Li et al., 1992). Zinc finger nucleases were designed after 
replacing the Fok1 DNA binding domain with the zinc finger domain 
with novel DNA binding specificities (Kim and Chandrasegaran, 1994). 
Since Fok1 nucleases act as a dimer, two ZFNs binding opposite strands 
are required to create a DSB (Smith et al., 2000). This technology has 
been successfully used to perform genome editing in human somatic 
cells (Moehle et al., 2007; Urnov et al., 2005), pluripotent stem cells 
(Lombardo et al., 2007), mice (Anguela et al., 2013; Sharma et al., 
2015) HIV patients (Tebas et al., 2014). 
 
1.10.4 Transcription activator like effector nucleases 
(TALENs) 
The discovery of the DNA recognition code of TALE proteins from the 
plant pathogen Xanthomonas provided a new way to design sequence-
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specific nucleases (Boch et al., 2009).  Each of the highly conserved 30-
35 amino acid long TALE repeat binds a single base pair in the DNA 
with specificity determined by two hypervariable residues (Deng et al., 
2012). These TALE repeats can be linked together in an array with 
custom DNA-binding specificities (Miller et al., 2011; Zhang et al., 
2011). Several procedures exist for engineering TALE arrays. The 
simplest one involves the cloning of the TALE array from different 
plasmids, each containing one TALE repeat (Sander et al., 2011a). 
Another method used  for cloning TALE arrays is Golden-Gate cloning 
platform, where multiple pieces are cloned simultaneously in the same 
reaction (Morbitzer et al., 2011). High-throughput methods include solid 
phase assembly or ligation independent cloning (Briggs et al., 2012; 
Schmid-Burgk et al., 2013). 
Similar to ZFNs, each TALE monomer is fused to the DNA cleavage 
domain of the Fok1 endonuclease in order to selectively cleave double 
stranded DNA after dimerization (Mussolino et al., 2011). TALENs 
have been shown to induce HDR and NHEJ in both human somatic cells 
and pluripotent stem cells (Hockemeyer et al., 2011; Reyon et al., 2012). 
TALENs can be designed to target any sequence with the only 
restriction of the presence of 5’ T, specified by the N-terminal domain 
for each array. The unlimited targeting range of TALEN combined with 
ease of generation makes them an attractive tool for genome editing. 
However, the large size of TALENs limits their application for in vivo 
genome editing using available viral delivery vehicles. In addition, the 
presence of tandem repeats in TALENs makes it difficult to package 
inside the viral vectors (Holkers et al., 2013).  
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1.10.5 CRISPR/Cas9 nucleases 
CRISPR/Cas9 are RNA guided nucleases derived from an adaptive 
immune system used by bacteria against invading plasmids and viruses. 
Work done by several groups over the years discovered the mechanism 
of insertion of short sequences of foreign nucleic acid into the CRISPR 
loci (Barrangou et al., 2007). The inserted foreign DNA undergoes 
transcription and processing into CRISPRRNA (crRNAs), which along 
with a trans-activating crRNAs (tracrRNAs) forms a complex with 
CRISPR associated (Cas) nuclease. The resulting ribonucleoprotein 
complex eventually loads on to the target sequence through Watson-
Crick base pairing followed by DNA cleavage. Further studies by 
Doudna, Charpentier and colleagues showed that this system could be 
reduced to only two components by forming a fusion between crRNA 
and tracrRNA into a single guide RNA (gRNA). Additionally, they also 
showed that targeting of Cas proteins to another locus could be achieved 
by changing only a small portion of gRNA (Jinek et al., 2012). After 
this discovery, several publications demonstrated the CRISPR/Cas-
mediated genome editing in mammalian cells (Cong et al., 2013; Jinek 
et al., 2013; Mali et al., 2013). 
The only limitation of the CRISPR/Cas system is the requirement of 
protospacer associated motif (PAM) located immediately 3’ to the target 
site. The PAM sequence is specific to the Cas protein derived from a 
particular species, such as the PAM sequence 5’ NGG is required for 
binding and cleavage by Cas9 derived from Streptococcus pyogenes 
(Chylinski et al., 2014);(Sternberg et al., 2014). 
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1.11 miRNA screening to find novel modulators of homologous 
recombination 
Micro RNA (miRNA) represents a subset of small, endogenous, 
regulatory RNAs of 21-25 nucleotides in length(Wahid et al., 2010). 
The miRNA genes are transcribed to generate primary miRNA (pri-
miRNA). This pri-miRNA is further processed by DROSHA within the 
nucleus into precursor miRNA (pre-miRNA). During the next phase, the 
pre-miRNA is exported out of nucleus into the cytoplasm by exportin-5 
(Exp-5). In the cytoplasm, these pre-miRNAs further get processed into 
mature miRNA by DICER, that finally loads the miRNA onto the 
Argonaute (Ago) protein to produce the RNA-induced silencing 
complex (RISC) (Wahid et al., 2010).  
A number of miRNAs have a role in several different cellular processes 
such as cell proliferation, cell death, fat metabolism, neuronal 
patterning, hematopoietic differentiation and immunity (He and Hannon, 
2004).  
Recently, miRNAs have emerged as one of the regulatory factors that 
influence HDR (Wei et al., 2012). Some studies highlight the fact that 
cells defective in miRNA biogenesis have uncontrolled cell cycle 
checkpoint and DNA repair (Huen and Chen, 2010; Pothof et al., 2009). 
Some miRNA such as miR-16, miR-24, miR-138, miR-183-96-182 
cluster, miR-155, miR-1255b, miR-148b and miR-193b have been 
implicated in DNA damage response (DDR) and DNA repair (Choi et 
al., 2014; Gasparini et al., 2014; Moskwa et al., 2011; Wang et al., 2012; 
Wei et al., 2012). Similarly, miR-196b enhances the radiosensitivity of 
gastric cells by targeting Rad23b (Shen et al., 2018). These finding 
suggests the important role of miRNA in DDR pathways.  
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miRNA regulatory network is highly complex since a single miRNA 
can target many transcripts and a single transcript can be targeted by 
many miRNA (Brodersen and Voinnet, 2009). So far, the precise role of 
miRNA in DDR is poorly understood.  
Several miRNA-based therapeutics have reached clinical trials. miR-34 
mimic reached clinical phase I trials for treating cancer, while miR-122 
has reached clinical trials phase II to treat hepatitis (Rupaimoole and 
Slack, 2017). Based on all the previous work that showed important 
roles of different miRNAs during HR, supported by its safe use during 
pre-clinical and clinical trials, makes the use of different miRNA 
mimics and Anti-miR as an attractive tool to modulate HR. For this 
purpose, a hi-throughput miRNA screening platform was planned to 
investigate the miRNA that modulate HR using special liver reporter 
stable cell line.  
For miRNA screening, HR reporter cells line were planned to get 
transfected with a library of miRNA mimics (Dharmacon) using a 
standard reverse-transfection protocol. Analysis of HR positive cells 
using an ImageXpress Micro high-content screening microscope 
(Molecular Devices) was programmed to be done 3 days after 
transfection (Eulalio et al., 2012). 
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2.1 Bilirubin purification protocol 
1. All the glass wares were washed sequentially with CH3OH/CHCl3 
2:1, CHCl3, CH3OH and dried. 
2. Bilirubin dissolution: 100 mg of commercial bilirubin (Sigma 
Aldrich-B 4126) was dissolved in CHCl3 (stabilized with ethyl 
alcohol, Carlo Erba, 438613) in a conical flask. Nitrogen gas was 
bubbled into the solution. Solution was warmed up to 60°C to allow 
complete dissolution of bilirubin. Temperature was always 
maintained above the boiling point of CHCl3 (62°C). 
3. Bilirubin filtration: Completely dissolved solution (amber coloured 
without any red precipitate) was filtered through a filter paper 
(Whatman 40 ashless, diameter: 11 cm- WHA1442110) pre treated 
with CHCl3 in a separatory funnel. Finally, filter paper was washed 
with CHCl3 again to remove most of the absorbed bilirubin. 
4. Washing: 250 ml of NaHCO3 (Sigma Aldrich-S5761) 0.1 M was 
added into the separatory funnel and shaken vigorously several 
times. Two miscible solutions were allowed to make two different 
layers. Aqueous solution and lipid interface were removed using a 
Pasteur pipette connected to a vacuum pump. This process was 
repeated again until lipid interface gets completely removed. Next, 
20% NaCl (Sigma Aldrich-433209) was added to reach same volume 
as CHCl3. Finally, bilirubin solution was washed two times with 
miliQ water. 
5. Filtration: After washing, organic phase was filtered as done in step 3 
into a conical flask. During this step, the filter paper in the funnel 
was always filled about 1/3 volume of CHCl3. UCB solution was 
added into the CHCl3 solution and then the filter paper was washed 
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with CHCl3. CHCl3 layer was always maintained in the filter cone 
layer.  
6. Crystallization: Nitrogen gas was bubbled into the flask with lower 
half of flask immersed in hot water (60-70°C). CH3OH (Sigma 
Aldrich-322415) was added drop wise up to 1:7 of initial volume of 
UCB solution. This process replaces the CHCl3 with CH3OH until 
total volume reduces to 1/5 of its original amount. At this point, 
solution started to become slightly cloudy with red crystals. The 
addition of CH3OH was continued till all the CHCl3 was evaporated 
from the solution and final volume was 1/20 of the original volume. 
Next, solution was kept in room temperature to allow crystal 
formation. After 10 min incubation at room temperature, 
centrifugation was done to remove CH3OH. Now, crystals were 
washed twice with CH3OH and allowed to dry. The purification was 
stopped at this step and dried bilirubin was stored at -20 °C. 
7. Secondary bilirubin dissolution: Bilirubin was again dissolved in 
CHCl3 and transferred into separatory funnel. Nitrogen gas was 
bubbled into the solution. 
8. Preparation of washing solution:  Washing solution was prepared by 
mixing 122 ml of 0.2 M Na 2 HPO 4 (Sigma Aldrich-255793), 78 ml 
of 0.2 M NaH2PO4 · H2O (Sigma Aldrich- 71507). pH was adjusted 
to 7. Then add 0.1 M NaCl in 1:1 ratio. 
9. Washing: Equal amount of washing buffer and UCB-Chloroform 
solution were added into the separatory funnel. Washes were done as 
mentioned above in the washing section. Washing with phosphate 
buffer were done 3 times followed by two washes with the mili Q 
water.  
10. Bilirubin concentration determination: Concentration of bilirubin 
was    determined by adding 20 µl of bilirubin sample into 980 µl of 
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CHCl3 in a   glass cuvette. CHCl3 was used as blank. Absorbance 
was determined at 453 nm. Concentration of bilirubin was 
determined using equation given below: 
      Absorbance x9.74 x dilution factor (50) = µg/ml x 1000/585 = 
µM. 
11. Fractionation: The bilirubin solution was aliquoted into several 
amber glass      tubes. Different aliquots were made, i.e. 1mg, 5mg, 
100 µg, 50 µg, 200 µg etc. Bilirubin was dried under gentle nitrogen 
gas in the presence of heat. These amber glass tubes were then 
stored at -20 °C under dark conditions. 
 
2.2 Bf determination 
Basic principle: The principle of this method is based on the fact that 
unbound bilirubin is oxidised to colourless compound by peroxide 
(H2O2) in the presence of peroxidase (HRP) (Sigma Aldrich-P8125) 
with 1st order kinetic; while albumin-bound form is protected from 
oxidation. In order to determine Bf, Kp of HRP enzyme was determined 
first by calculating the decrease in Abs440 following addition of HRP and 
H2O2 to 1-3 µM bilirubin. 
 
2.2.1 Kp determination: Reagents: 1µg of bilirubin was 
dissolved in 340 µl of DMSO. 2mg of HRP was dissolved in 2ml PBS 
buffer. 5µg/ml working solution was prepared by mixing 100 µl of stock 
solution in 20 ml PBS buffer. 550mM H2O2 was prepared by mixing 200 
µl to 6ml PBS.  
 
 
2. Materials and Methods 
 
49 
Protocol:  
1. 200 µl of bilirubin solution was added into 2.8 ml PBS and mix 
properly. Absorbance was measured at 440 nm. 
2. 10 µl of H2O2 was added to the bilirubin solution. 2-3 
concentrationsof H2O2 were tested to make sure if the concentration 
was not rate limiting. 
3. 110 µl of diluted HRP solution was added to the bilirubin solution 
and mixed properly. Absorbance was measured at 440 nm and change 
in absorbance was measured for 60 seconds. Kp was calculated using 
this formula:  
       Kp= Vo/ ([Bf]x[HRP]), where Vo= initial oxidation velocity, can be  
represented as ΔΑbs/min. 
 
2.2.2 Bf determination: 
1. 1µg of bilirubin was dissolved in 340 µl of DMSO. Bilirubin stock 
solution was added to culture medium to create different bilirubin: 
albumin ratio ranging from 0.2-1. Initial absorbance was calculated 
by measuring the absorbance at 468 nm. 
2. 10µl of 250 nM of H2O2 was added to the medium and mixed 
properly. 
3. 25 µl of different concentration of HRP (0.6-2.5 µg/ml) was added to 
the medium and mixed properly. Absorbance was determined at 468 
nm and change in absorbance was calculated for 30 secs.  
    4. After calculating change in Abs using different HRP concentration, 
Bf was calculated using the formula: 
               Apparent Bf: ΔAbs/min /Kp x [HRP] 
5. The swift change in Abs reflects the true Bf, but rate of oxidation after 
that represents “apparent Bf”. Apparent Bf represents the steady state 
2. Materials and Methods 
 
50 
equilibirium between bilirubin-albumin dissociation and enzyme 
oxidation. In order to determine real Bf, the assay was done at 2-3 
HRP enzyme concentration. 1/ [apparent Bf] is proportional to 1/ Bf+ 
[HRP], and Bf was determined by making a plot between 
concentration of  HRP used and 1/apparent Bf, where y intercept in 
the plot represents real Bf. 
 
2.3 Cell culture and treatment with bilirubin 
HeLa DR GFP cells were kindly gifted by Dr. E. Avvedimento 
(Cuozzo et al., 2007). HeLa DR GFP and HeLa cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM, Thermo Fischer 
Scientific, GIBCO) supplemented with 10% Fetal calf serum (FCS) 
and 1% antibiotic & antimycotic solution (Sigma Aldrich-A5955). 
          SH SY 5Y cells were cultured in Eagle’s minimum essential 
medium F12 (EMEM/F12, Sigma Aldrich) medium supplied with 
15% FCS, 1% antibiotic & antimycotic solution (Sigma Aldrich-
A5955), 1% MEM non-essential amino acid solution (Sigma 
Aldrich M7145). 
For bilirubin treatment, bilirubin was dissolved in DMSO (17ul per 
50 µg of bilirubin). Appropriate amount of UCB solution was added 
to DMEM and EMEM/F12 media and bilirubin concentration in 
media was calculated by taking absorbance at 468 nm using 
spectrophotometer. After confirming the required amount of 
bilirubin in culture media, it was added to cells. 
 
2.4 Cell viability by MTT assay 
 The MTT assay is employed to calculate cellular viability 
spectrophotometrically. The yellow MTT (3-(4, 5-dimethylthiazolyl-
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2)-2,5-diphenyltetrazolium bromide) reagent is reduced by 
metabolically active cells, by dehydrogenase enzymes, to generate 
reducing equivalents such as NADH and NADPH. The resulting 
intracellular purple formazan is solubilized and quantified by 
spectrophotometry. Reduction in cellular viabilty can be seen by 
decrease in absorbance. 
1. 80,000 SH SY 5Y cells/well were seeded in 24 well plate one day 
before experiment.  
        2. After 14-16h, media was removed and cells were washed twice with 
PBS and 70 nM and 140 nM of bilirubin was added to cells, ranging 
from 1h, 4h and24h. Bilirubin containing culture medium was 
prepared as described in section 2.3.3. Cellular viability was 
determined using 3(4, 5-dimethylthiazolyl 2)2, 5 diphenyl tetrazolium 
(MTT) assay at respective time points. 5 mg/ml stock of MTT (Sigma 
Aldrich) was prepared by dissolving MTT in PBS. The stock solution 
of MTT was finally diluted in growth medium to a final concentration 
of 0.5 mg/mL. The cells were incubated with the MTT solution for 1h 
at 37 °C.  
4. After incubation, the medium was discarded, the MTT formazan 
crystals  were dissolved in 400 µl of DMSO, and the plate was shaken 
gently for 15 min and absorbance was recorded at 562 nm using Bio-
Rad iMark microplate reader. Results were expressed as percentage 
of control cells (cells exposed to media only) which was considered 
as 100% viability. 
 
To check the viability of HeLa DR GFP cells, 50,000 cells were 
plated in 24 wells culture plate one day before experiment. After 14-
16h, media was removed from cells and washed twice with PBS and 
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140 nM of bilirubin was added to cells for different time intervals 
ranging from 1h, 4h and 24h as described in section 2.3. Cell viability 
was determined using MTT test as discussed above.  
 
2.5 Plasmids used for transfection 
     The pCBA Isce1 plasmid was purchased from Addgene (#26477); 
the pHRG-TK plasmid was purchased from Promega; the pIM EJ5-
GFP plasmid was purchased from Addgene (#44026). 
The pCBA Isce1 plasmid is an expression vector that contains the I-
SceI endonuclease cDNA under the transcriptional control of the 
CMV enhancer and chicken β-actin promoter; it has theβ-globin 
poly-A signal. It is used to introduce a DSB at a genomic Isce1 site. 
The pHRG-TK is a Renilla luciferase expression vector,with the 
HSV TK promoter and SV-40 poly-A signal; the pIM EJ5-GFP is a 
NHEJ substrate vector having the CMV enhancer and chicken β-
actin promoter, and β-globin poly-A signal. 
 
2.6 HeLa DR GFP cells transfection and bilirubin treatment 
1. For transfection of HeLa DR GFP cells, 50,000 cells were seeded in 
24 wells plates 24h before transfection.  
2. After 14-16h, cells were transfected with 300 ng of plasmid encoding 
Isce1 (pCBA Isce1) using Effectine tranfection reagent (Qiagen-
301427) according to manufacturer protocol in the case of time-course 
experiments. Transfection complexes were removed 6-7h after 
transfection and cells were washed twice with PBS and bilirubin was 
added to cells as described above in section 2.3.  
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Bilirubin containing media was removed after different time points (24h 
and 48h and cells were washed with phosphate buffer saline (PBS) two 
times and new media was added to cells. For all the other experiments, 
cells were co-transfected with 300 ng of plasmid encoding Isce1 (pCBA 
Isce1) and 10 ng of plasmid encoding renilla (pHRG TK Renilla). 
Transfection complexes were removed 6-7h after transfection and cells 
were washed twice with PBS and bilirubin was added to cells as 
discussed above in section 2.3. In the case of NAC experiments, Cells 
were pre-treated with 2 mM NAC (Sigma Aldrich) for 1h, followed by 
co-treatment with bilirubin using protocol discussed above in section 
2.3. Fresh NAC was added after every 24h.  
3. Cells were analysed for GFP fluorescence 72h post-transfection using 
FL1 channel in BD FACS Calibur cell analyser. Dead cells were 
excluded from the analysis by using proper gating of the live cells.  
4. For the time course experiment, data were normalised for the 
transfection efficiency by calculating the overall transfection 
efficiency after transfecting the cells with the EGFP plasmid in 
parallel wells. In order to do normalisation, total percentage of GFP 
positive cells per condition was divided by the calculated transfection 
efficiency. The value of DMSO treated cells were taken as 1 after 
normalisation for transfection efficiency. While for all other 
experiments involving HeLa DR GFP cells, cells were co-transfected 
with the pHRG-TK plasmid and data were normalised using the 
renilla luciferase activity determined in the same well. In order to do 
normalisation, the total percentage of GFP positive cells per condition 
was divided by renilla luciferase activity of same well. The value of 
Isce1 DMSO sample was taken as 1 after normalisation for 
transfection efficiency. 
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2.7 HeLa cells transfection and bilirubin treatment 
1. For transfection of HeLa cells, 80,000 cells were seeded in 24 wells 
plates 24h before transfection.  
         2. After 14-16h, cells were co-transfected with 100 ng of NHEJ plasmid   
pIM   EJ5- GFP, 300ng of plasmid encoding Isce1 (pCBA Isce1) and 10 
ng of plasmid encoding renilla (pHRG TK renilla) using Effectine 
transfection reagent (Qiagen- 301427) according to manufacturer 
protocol. Transfection  complexes were removed 6-7h after transfection. 
Cells were washed twice with PBS and bilirubin was added as discussed 
above in section 2.3.  
3. Cells were analysed for GFP fluorescence 72h post-transfection using 
FL1 channel in BD FACS Calibur cell analyser. Dead cells were 
excluded from the analysis by using proper gating of the live cells.  
4. Data was normalised using the renilla luciferase activity corresponds 
to same well. In order to do normalisation, total percentage of GFP 
positive cells per condition was divided by renilla luciferase activity of 
same well. The value of Isce1 DMSO was taken as 1 after normalisation 
for transfection efficiency. 
 
 2.8 SDS PAGE and Western Blot analysis 
  1. For Western Blot analysis, 150,000 SH SY 5Y cells were seeded in 
    35 mm culture dishes one day before experiment.  
2. After 14-16h, bilirubin containing culture media was added to cells. 
In the case of NAC experiments, cells were pre-treated with different 
concentrations  of NAC (0.1, 0.3 and 0.4 mM) followed by co-treatment 
with bilirubin for 30h. Cells were harvested at respective time points 
after bilirubin treatment in RIPA buffer (150 mM NaCl, 5 mM 0.5 mM 
EDTA (pH-8), 50 mM Tris (pH-8), 1% NP-40, 0.5% Sodium 
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deoxycholate, 0.1% SDS) containing SIGMAFAST (SigmaAldrich) 
protease inhibitor, Serine/Threonine-phosphatase inhibitor 1mM 
SodiumFluoride (NAF) and 1mM Tyrosine phosphatase inhibitor 
Sodium orthovanadate (Na3VO4). 
  3. Protein concentration was determined using Bradford reagent (Bio 
Rad).  
  4. Total protein lysate (50 µg) was loaded on 12 % SDS PAGE gel and 
transfer-ed into nitrocellulose membrane (GE healthcare lifescience- 
AMERSHAM) using wet transfer. The correct transfer of protein was 
confirmed by Ponceau (Sigma Aldrich) staining. Ponceau stain was 
cleaned using water. Blots were blocked in appropriate blocking solution 
(5% BSA for 2AX antibody, 5% milk for P53 and Actin) for 1h at 
room temperature. Blots were incubated in appropriate primary antibody 
O/N at 4 o C (Table 1).  
5. Next day blots were washed 3 times with TBS 0.2% Tween-20 for 10 
minutes and incubated with secondary antibody for 1h at room 
temperature followed by 3 washing with TBS 0.2% Tween-20 for 10 
minutes (Table 1). After washing steps, blots were developed with ECL 
reagent (Amersham Biosciences).  
6.Images were taken in Uvitech Cambridge ECL machine. Densitometry  
analysis of protein bands were done using Quantity one software (Bio-
Rad). 
 
For HeLa DR GFP cells, cells were transfected and treated with 
bilirubin as discussed in section 2.6. Cells were harvested 72h post 
transfection in RIPA buffer. Western Blot was done as discussed above 
for SH SY 5Y cells. 
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Table 1: List of all antibodies used for Western Blot- Antibody name, 
company name, dilution and MWs are given. 
Antibody  Company MW           Dilution 2o Antibody 
   WB IF  
2AX Millipore(Clone 
JBW301) 
17 1:2000 1:200 Anti-Mouse 
(DAKO for 
WB), (Thermo 
Scientific) for IF. 
Actin Sigma Aldrich 
(A5060) 
42 1:2000  Anti-Rabbit 
(DAKO) 
P53 Santacruz 
biotechnology 
(DO-1) 
53 1:2000  Anti-Rabbit 
(DAKO) 
 
2.9 Immunofluorescence analysis 
1. For Immunofluorescence analysis, 150,000 SH SY 5Y cells were 
seeded in 35 mm culture dishes.  
2. After 14-16h, SH SY 5Y cells were treated with 140 nM bilirubin. In 
the case of NAC treatment, cells were co-treated with bilirubin and 0.4 
mM NAC for 30h as discussed above in section 2.8.  
3. After 30h, media was removed and cells were washed twice with 
PBS. It was followed by fixing of cells in ice cold 4% paraformaldehyde 
(PFA) for 10 min at room temperature. After 10min, PFA was removed 
and cells were washed thrice with PBS.  
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4. Next, cells were permeabilized using PBS Tween-20 0.1% for 10 
mins. After 10 min, PBS Tween-20 0.1% was removed and cells were 
washed twice with PBS.  
5. After permeabilization, cells were blocked in 2% goat serum in PBS 
for 1h at room temperature.  
6. After blocking, cells were incubated in primary antibody at 37o C for 
2h (Table 1). After this, cells were washed thrice with PBS for 5 
minutes.  
7. After washing step, cells were incubated for 20 minutes at 37o C with 
anti-mouse secondary antibody (Alexa Fluor 488- Thermo Fischer 
Scientific) followed by 3 times washing with PBS. Nuclei were 
visualized using TO- PRO-3 iodide dye (T3605). Images were acquired 
using Zeiss Meta confocal  micro scope using 63X oil objective. At 
least, 10 images per slide were taken. Quantification was done after 
counting percentage of cells containing 10> foci in total of 200 cells. 
 
1. For immunofluorescence analysis of HeLa DR GFP cells, 50,000  
cells were seeded in 24 well culture plate. 
     2. After 14-16h, cells were transfected and treated with bilirubin as 
discussed in section 2.6.  
     3. Media was removed 72h post transfection and cells were washed 
twice with PBS. It was followed by fixing of cells in ice cold 4% 
Paraformaldehyde (PFA) for 10 min at room temperature. After 
10min, PFA was removed and cells were washed twice with PBS.  
4. Next, cells were permeabilized using PBS Tween-20 0.1% for 10 
mins. After 10 min, PBS Tween-20 0.1% was removed and cells were 
washed thrice with PBS. 
5. After permeabilization, cells were blocked in 2% Bovine serum 
albumin in PBS for 1h at room temperature.  
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6. After blocking, cells were incubated in primary antibody at 37o C for 
2h (Table 1). After this, cells were washed thrice with PBS for 5 
minutes.  
7. After washing step, cells were incubated for 20 minutes at 37o C anti 
mouse  
secondary antibody (Rabbit anti mouse Rhodamine-Thermo Fischer 
Scientific) followed by 3 times washing with PBS. Nuclei were 
visualized using TO-PRO-Iodide dye (T3605). Images were acquired 
using Zeiss Meta confocal Microscope using 63X oil objective. At least, 
10 images per slide were taken. Quantification was done after counting 
percentage of cells containing 10> foci in total of 200 cells. 
 
2.10 Cell cycle analysis 
    1. HeLa cells were treated with 140 nM of Bilirubin for 48h as discussed 
in section 2.3.  
    2. After 48h of treatment with bilirubin, media was removed and cells 
were washed twice with PBS. Next, cells were trypsinized and 
washed two times with PBS. 
    3.  After washing, cells were resuspended in 200 µl PBS and 800 µl of 
ethanol and tubes were inverted several times and stored O/N at 20o 
C.  
    4.  Next day, cells were spin down, the pellet was washed two times with 
PBS and resuspended in 1 ml of PI solution in sodium citrate (5 
µg/µl),which guarantees an osmotic shock to the cells. Add 10-20 ul 
of 0.1% NP40 stock solution (in order to allow the permeabilization 
of the cells) and RNAse (0.5 mg/ml) to degrade the RNA and allow a 
clear identification of cell cycle phases. 
    5. 5000 cells were analysed for cell cycle analysis using FACS Calibur 
cell analyser. 
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2.11 Effect of bilirubin on etoposide induced DNA damage. 
    1. HeLa cells were treated with 140 nM of Bilirubin for 24h as discussed 
in section 2.3.  
    2. After 24h of treatment with bilirubin, media was removed and cells 
were washed twice with PBS. Next, cells were treated with 100 µM 
etoposide for 2h. 
    3. After 2h, etopsoide was removed and cells were treated again with 140 
nM free bilirubin for different time intervals. Cells were harvested at 
different time points and western blot was done to check the level of 
2AX. 
     
2.12 Subcloning of new codon optimised Exon4 to generate a new 
donor AAV vector 
Digestion of pUC57 new codon optimised Exon4 and PBK plasmids 
was done using the protocol given below: 
   0.5 µl (500 ng) pUC57 Exon4 plasmid/PBK 
   0.5 µl BamHI (0.5 U) (New England Biolabs) 
   1.5 µl 10X buffer (New England Biolabs) 
   12.5 µl Water 
The digested product was checked on 1% Agarose gel. Both the 
plasmids were dephosphorylated at 5’ end to prevent self ligation after 
treatment with calf intestinal phosphatase at 37 degree celsius for 60 
minutes. Then the enzyme was inactivated after incubation at 65 degree 
celsius for 20 minutes. 
The digested pUC57 Exon4 plasmid (insert) was then ligated directly 
without purification into BamHI digested PBK plasmid backbone 
(vector) using the protocol given below: 
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Vector – 1 µl (33 ng)    Vector – 2 µl (66 ng) 
Insert- 3 µl (50 ng)    Insert- 4 µl (200 ng) 
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)                          T4 ligase- 0.5 µl (0.5 U)                          
Water- 9 µl      Water- 7 µl      
Self ligation control reaction  Undigested control reaction 
Vector – 1 µl (33 ng)    Vector – 1 µl (33 ng)   
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)      Water- 13 µl    
Water- 12 µl          
All the ligation mixtures were incubated at RT for 4-5h and transformed 
into DH5αcompetent cells. The competent cells were stored at -20 
degree celsius and thawed in ice for 10 minutes. After thawing of cells, 
4 µl of β-mercaptoethanol (1.42M) was added to 100 µl of competent 
cells in order to increase the competence of cells. Next, half of the 
ligation mixture from each reaction was added to competent cells and 
mixed properly and kept incubated on ice for 15-20 minutes. After 
incubation on ice, heat shock at 42 degree celsius for 1 minute in a water 
bath was given to the competent cells. After heat shock, bacteria were 
kept on ice for 5 minutes. After this, warm LB media was added to the 
cells and incubated for 1h at 37 degree celsius in order to allow bacteria 
to recover and express the antibiotic resistance gene. After the 
incubation period end, cells were plated in LB agar containing plate 
with appropriate antibiotics (ampicillin/kanamycin) and let them grow 
overnight at 37 degree celsius. 
The positive clones were confirmed by restriction digestion. Different 
plasmids were isolated from bacterial colonies using Promega plasmid 
2. Materials and Methods 
 
61 
isolation kit. The presence of insert in different plasmids was confirmed 
by restriction digestion protocol as given below: 
   1 (1µg) PBK Exon4 plasmid 
   1 µl BamHI (1U) (New England Biolabs) 
   2 µl 10X buffer (New England Biolabs) 
   11 µl Water 
The digested product was checked on 1% Agarose gel.  
To clone new Exon4 into AAV vector in order to generated new codon-
optimised vector plasmid, the old AAV donor vector was digested with 
BamHI enzyme to replace old Exon4 with new codon optimised Exon4. 
 
1 (1µg) pAAV old Exon4 plasmid 
   1 µl BamHI (1U) (New England Biolabs) 
   2 µl 10X buffer (New England Biolabs) 
   11 µl Water 
The digested product was checked on 1% Agarose gel. The pAAV old 
donor was dephosphorylated at 5’ end to prevent self ligation after 
treatment with calf intestinal phosphatase at 37 degree celsius for 60 
minutes. Then the enzyme was inactivated after incubation at 65 degree 
celsius for 20 minutes. 
Next, Exon4 derived from PBK new Exon4 plasmid (insert) digested 
with BamHI as done above, was cloned directly without purification 
step into BamHI digested pAAV old donor vector (Vector) using the 
protocol given below: 
Vector - 2 µl (15 ng)     
Insert- 1.8 µl (60 ng)     
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Ligase buffer (10X) - 1.5 µl     
T4 ligase- 0.5 µl (0.5 U)                           
Water- 9 µl        
  
Self ligation control reaction  Undigested control 
reaction 
Vector – 2 µl (15 ng)    Vector – 1 µl (33 ng)   
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)      Water- 13 µl    
Water- 12 µl  
All the ligation mixtures were incubated at RT for 4-5h and transformed 
into XL1 Gold competent cells in order to prevent recombination 
between ITRs of pAAV vector. The protocol used for transformation 
was the same as described above.  
The positive clones were confirmed by restriction digestion. Different 
plasmids were isolated from bacterial colonies using Promega plasmid 
isolation kit. The presences of the insert in different plasmids were 
confirmed by restriction digestion as described below: 
   1 (1µg) pAAV new Exon4 donor plasmid 
   1 µl NcoI (1U) (New England Biolabs) 
   2 µl 10X buffer (New England Biolabs) 
   11 µl Water 
The digested product was checked on 1% Agarose gel.  
Orientation of the positive clone was checked using restriction digestion 
as described below: 
2 µl (1µg) pAAV new Exon4 donor plasmid 
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   1 µl SacI (1U) (New England Biolabs) 
   2 µl 10X buffer (New England Biolabs) 
   10 µl Water 
The digested product was checked on 1% Agarose gel.  
 
2.13 TALEN activity analysis in wild type animals using genomic 
PCR followed by restriction digestion 
Genomic PCR was done from genomic DNA isolated from the liver of 
TALEN treated mice using the protocol given below: 
   gDNA- 3 µl 
   10X polymerase Buffer- 5 µl 
   MgCl2(50 nM) - 8.4 µl 
   dNTP (25 mM) - 2.5 µl 
   UGTF3- 1.7 µl 
   UGT9934 Rev- 1.7 µl 
   Taq polymerase- 0.75 µl 
   Water- 26.95 µl  
    
   95- 30 min 
   95- 30 sec 
   60- 40 sec 35 cycles 
   72- 40 sec 
   72- 3 min 
The genomic PCR product was confirmed after running in 1% agarose 
gel. 
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The genomic PCR products were then digested with NcoI restriction 
enzyme in order to investigate the presence of NcoI resistant site due to 
TALEN activity and NHEJ DSB DNA repair. 
7 µl genomic PCR product 
   0.5 µl NcoI HF (0.5U) (New England Biolabs) 
   2 µl 10X  buffer (New England Biolabs) 
   10.5 µl Water 
The digested product was checked on 1% Agarose gel.  
Primers used for genomic PCR: 
Primer name Sequence (5’-3’) 
UGTF3 ACTCGGGCATTCATCACACACTCTGG 
UGT9934 Rev GCTGTAAGACAATCTTCTCC 
 
2.14 gRNA activity analysis in Hep3B cells using the pGL3 EXON4 
reporter plasmid 
Four different gRNAs targeting Exon4 of Ugt1 locus were designed. 
The gRNA-coding oligonucleotides were purchased from Eurofin 
Genomics in the form of lyophilized, non-phosphorylated single-
stranded oligonucleotides, and were resuspended inwater to obtain a 
stock concentration of 1μg/μl. Next, 5'-phosphorylation of every single-
stranded oligonucleotide was performed by setting up reaction 
containing water, 100 ng/μl single-stranded oligonucleotide, 1X PNK 
buffer (Roche), 66 μM ATP (Roche), and 10 U of Poly-Nucleotide 
Kinase (Roche). The reaction mixture was further incubated at 37 
degree celsius for 1h. After 1h-incubation, 10 U of PNK was added, and 
the reaction was incubated again for 1h at 37°C.  
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Once phosphorylated, complementary oligonucleotides were 
annealedtogether to generate the phosphorylated double-stranded 
oligonucleotides to be cloned into pX601 plasmid vector (Addgene) . In 
order to anneal oligos, equal volumes of complementary phosphorylated 
oligos were mixed together and incubated for 5 minutes in a 95°C water 
bath. After this the water bath was cooled down to room-temperature. 
pX601 plasmid digested with BsaI restriction enzyme was finally used 
to clone annealed oligos. The presence of the corresponding gRNA was 
further confirmed by sequencing analysis.  
For gRNA activity analysis 70,000 Hep3B cells were seeded in 24 well 
culture plates 14-16h before transfection. Next day Hep3B cells were 
co-transfected with different concentrations of gRNA, 400 ng of pGL3 
EXON4 and 40 ng renilla plasmid using lipofectamine reagent 
according to manufacturer protocol. The activity of different gRNAs 
was calculated after measuring luciferase activity.  
 
2.15 TALEN activity analysis in Hep3B cells using the pGL3 
EXON4 reporter plasmid 
For gRNA activity analysis 70,000 Hep3B cell were seeded in 24 well 
culture plate 14-16h before transfection. Next day Hep3B cells were co-
transfected with different concentrations of NcoI targeting TALEN 
pairs, 400 ng of pcDNA5 EXON4 and 40 ng renilla plasmid using 
lipofectamine reagent according to manufacturer protocol. The activity 
of TALEN was calculated after measuring luciferase activity.  
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2.16 Subcloning of Luciferase and LuciFeExon4Ferase into 
pcDNA5/FRT plasmid 
In order to clone the Luciferase encoding gene into the pcDNA5/FRT 
plasmid, the pGL3 Luciferase plasmid was digested according to the 
protocol given below: 
0.5 (1µg) pGL3 luciferase plasmid 
   1 µl HindIII (1U) (New England Biolabs) 
   1 µl XbaI (1U) (New England Biolabs) 
   2 µl 10X buffer (New England Biolabs) 
   15.5 µl Water 
The digestion of the pGL3 control plasmid was confirmed after running 
in 0.8% agarose gel. 
In the next step, luciferase insert derived from pGL3 plasmid was 
cloned directly without purification step into PBK vector digested with 
HindIII and XbaI. 
Vector - 1 µl (40 ng)    Vector- 1 µl (40 ng) 
Insert- 4 µl (80 ng)    Insert- 8 µl (160 ng) 
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)                           T4 ligase- 0.5 µl (0.5 U)                          
Water- 8 µl       Water- 4 µl 
Self ligation control reaction  Undigested control reaction 
Vector – 1 µl (40 ng)    Vector – 1 µl (40 ng)   
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)      Water- 12.5 µl   
Water- 12 µl  
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All the ligation mixtures were incubated at RT for 4-5h and transformed 
into DH5α competent cells as done before. 
The positive clones were confirmed by restriction digestion using the 
protocol given below: 
5 µl (1µg) PBK luciferase plasmid 
   1 µl HindIII (1U) (New England Biolabs) 
   1 µl XbaI (1U) (New England Biolabs) 
   2 µl 10X buffer (New England Biolabs) 
   11 µl Water 
The digestion of the PBK luciferase plasmids was confirmed after 
running in 0.8% agarose gel. 
In the next step, the luciferase insert derived from the PBK luciferase 
plasmid digested with HindIII and NotI was cloned directly without 
purification step into pcDNA5/FRT vector digested with HindIII and 
NotI enzymes. Ligation was performed using the protocol given below: 
Vector - 1 µl (20 ng)    Vector- 1 µl (40 ng) 
Insert- 4 µl (80 ng)    Insert- 8 µl (160 ng) 
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)                           T4 ligase- 0.5 µl (0.5 U)                          
Water- 8 µl       Water- 4 µl 
Self ligation control reaction  Undigested control reaction 
Vector – 1 µl (40 ng)    Vector – 1 µl (40 ng)   
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)      Water- 12.5 µl   
Water- 12 µl  
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All the ligation mixtures were incubated at RT for 4-5h and transformed 
into DH5αcompetent cells as done before. 
The positive clones were confirmed by restriction digestion using the 
protocol given below: 
0.5 µl (1µg) PBK luciferase plasmid  0.5 µl (1µg) PBK luciferase plasmid 
  
1 µl HindIII (1U) (New England Biolabs) 1 µl HindIII (1U) (New England 
Biolabs) 
1 µl SpeI (1U) (New England Biolabs) 1 µl PstI (1U) (New England Biolabs) 
2 µl 10X buffer (New England Biolabs) 2 µl 10X buffer (New England Biolabs) 
15.5 µl Water     15.5 µl Water 
Next, LuciFeExon4Ferase was subcloned from 
pGL3LuciFeExon4Ferase was subcloned into pcDNA5/FRT. First, 
pGL3LuciFeExon4Ferase was digested with HindIII and XbaI as given 
below: 
2 µl (1µg) PBK luciferase plasmid 
   1 µl HindIII (1U) (New England Biolabs) 
   1 µl XbaI (1U) (New England Biolabs) 
   2 µl 10X buffer (New England Biolabs) 
   14 µl Water 
The digestion of pGL3LuciFeExon4Ferase was confirmed by running 
the digestion product on 0.8% gel.  
The digested product was then directly cloned without purification step 
into HindIII and XbaI digested PBK vector. 
Vector - 1 µl (16 ng)    Vector- 1 µl (16 ng) 
Insert- 4 µl (70 ng)    Insert- 8 µl (140 ng) 
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Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)                           T4 ligase- 0.5 µl (0.5 U)                          
Water- 8 µl       Water- 4 µl  
Self ligation control reaction  Undigested control reaction 
Vector – 1 µl (16 ng)    Vector – 1 µl (16 ng)   
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)      Water- 12.5 µl   
Water- 12 µl  
All the ligation mixtures were incubated at RT for 4-5h and transformed 
into DH5αcompetent cells as described before. 
The positive clones were confirmed by restriction digestion using the 
protocol given below: 
3 µl (1µg) PBK LuciLuciFeExon4Feraseplasmid 
   1 µl HindIII (1U) (New England Biolabs) 
   1 µl XbaI (1U) (New England Biolabs) 
   2 µl 10X buffer (New England Biolabs) 
   13 µl Water 
The digestion of the PBK LuciFeExon4Ferase plasmid was confirmed 
by running the digestion product on 0.8% gel.  
The HindIII and NotI digested product was then directly cloned without 
purification step into HindIII+ NotI digested pcDNA5/FRT vector. 
Vector - 1 µl (30 ng)    Vector- 1 µl (30 ng) 
Insert- 3 µl (90 ng)    Insert- 6 µl (180 ng) 
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)                           T4 ligase- 0.5 µl (0.5 U)                          
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Water- 9 µl      Water- 6 µl  
Self ligation control reaction  Undigested control reaction 
Vector – 1 µl (30 ng)    Vector – 1 µl (16 ng)   
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 0.5 µl (0.5 U)      Water- 12.5 µl   
Water- 12 µl  
All the ligation mixtures were incubated at RT for 4-5h and transformed 
into DH5αcompetent cells as done before. 
The positive clones were confirmed by restriction digestion using 
protocol given below: 
3 µl (1µg) pcDNA5 LuciFeExon4Ferase plasmid  
1 µl HindIII (1U) (New England Biolabs) 
1 µl XcmI (1U) (New England Biolabs) 
2 µl 10X buffer (New England Biolabs) 
13 µl Water 
3 µl (1µg) pcDNA5 LuciFeExon4Ferase plasmid  
1 µl BamHI (1U) (New England Biolabs) 
2 µl 10X buffer (New England Biolabs) 
14 µl Water 
The digestion of pcDNA5 LuciFeExon4Ferasewas confirmed by 
running the digestion product on 0.8%  agarose gel.  
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2.17 Luciferase and LuciFeExon4Ferase stable clone generation 
To generate luciferase stable clone, Hep3B cells were used. Due to the 
absence of any antibiotics resistance gene in pcDNA5/FRT plasmid, we 
decided to co-transfect the cells with pBABE plasmid containing 
hygromycin resistance gene. In a pilot experiment, 200 µg/ml was used 
to kill untransfected cells. In order to generate the luciferase stable 
clone, Hep3B cells were co-transfected with 14 µg of pcDNA5 
Luciferase and 1.4 µg pBABE plasmids in a 10 cm cell culture plate 
using lipofectamine reagent according to manufacturer instructions. The 
cells were exposed to hygromycin pressure 5 days after transfection for 
10 days to kill untranfected cells. After 10 days of antibiotic pressure, 
cells were serially diluted to get single cells clones.  
Only 9 clones survived the hygromycin pressure after serial dilution and 
the activity of individual clones was determined using the luciferase 
assay.  
To generate LuciFeExon4Ferasestable clone Hep3B cells were co-
transfected with 16µg of pcDNA5 LuciFeExon4Ferase and 1.6 µg 
pBABE plasmid in a 10 cm cell culture plate using lipofectamine 
reagent according to manufacturer instructions. The cells were exposed 
to hygromycin pressure 5 days after transfection for 10 days to kill 
untranfected cells. After 10 days of antibiotic pressure, cells were 
serially diluted to get single cells clones.  
Only 11 clones survived the hygromycin pressure after serial dilution 
and the activity of individual clones were determined using luciferase 
assay after co-transfecting all the individual clones with 700 ng Nco 
targeting TALEN pairs and 40 ng renilla plasmid in 24-well cell culture 
plate using lipofectamine reagent according to manufacturer 
2. Materials and Methods 
 
72 
instructions. The activities of individual clones were determined by the 
luciferase assay. 
 
2.18 Subcloning of luciferase and LuciFeExon4Ferase into pcDNA3 
plasmid 
Sucloning of luciferase and LuciFeExon4Ferase into pcDNA3 plasmid 
was done using PBK luciferase and PBK LuciFeExon4Ferase plasmids 
cloned in Section 2.5. 
The PBK clone was digested with HindIII and XbaI using protocol 
given below:  
5 µl (1µg) PBK luciferase plasmid  
1 µl HindIII (1U) (New England Biolabs) 
1 µl XbaI (1U) (New England Biolabs) 
2 µl 10X buffer (New England Biolabs) 
11 µl Water 
The digestion of PBK clones was confirmed by running the digestion 
reactions on 1% agarose gel.  
Next, The HindIII and XbaI digested product was then directly cloned 
without purification step into HindIII and XbaI digested pcDNA3 
vector. 
Vector – 1 µl (60 ng)    Vector- 1 µl (60 ng) 
Insert- 2.27 µl (22.25 ng)   Insert- 4.54µl (22.25ng) 
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 1 µl (1 U)                            T4 ligase- 1 µl (1 U)                          
Water- 9.23 µl     Water- 6.96 µl  
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Self ligation control reaction  Undigested control 
reaction 
Vector – 1 µl (60 ng)    Vector – 1 µl (60 ng)   
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 1 µl (1 U)      Water- 12.5 µl   
Water- 11.5 µl  
All the ligation mixtures were incubated at RT for 4-5h and transformed 
into DH5α competent cells as done before. 
The positive clones were confirmed by restriction digestion using 
protocol given below: 
 
 
2 µl (1µg) pCDNA3 luciferase plasmid 2 µl (1µg) pCDNA3 luciferase 
plasmid 
1 µl HindIII (1U) (New England Biolabs) 1 µl HindIII(1U) (New England 
Biolabs) 
1 µl XbaI (1U) (New England Biolabs) 1 µl XcmI (1U) (New England 
Biolabs) 
2 µl 10X buffer (New England Biolabs) 2 µl 10X buffer (New England 
Biolabs) 
14 µl Water     14 µl Water 
2 µl (1µg) pcDNA3 luciferase plasmid   
1 µl NdeI (1U) (New England Biolabs)  
1 µl XcmI (1U) (New England Biolabs)  
2 µl 10X buffer (New England Biolabs)  
14 µl Water   
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Next, in order to clone LuciFeExon4Ferase construct into the pcDNA3 
vector, the PBK clones were digested with HindIII and XbaI using 
protocol given below:  
5 µl (1µg) PBK LuciFeExon4Feraseplasmid  
1 µl HindIII (1U) (New England Biolabs) 
1 µl XbaI (1U) (New England Biolabs) 
2 µl 10X buffer (New England Biolabs) 
11 µl Water 
The digestion of PBK clones were confirmed by running the digestion 
reactions on 1% agarose gel.  
Next, The HindIII and XbaI digested product was then directly cloned 
without purification step into HindIII and XbaI digested pcDNA3 
vector. 
Vector – 1 µl (60 ng)    Vector- 1 µl (60 ng) 
Insert- 1.48 µl (55.75 ng)   Insert- 2.96 µl (55.75 ng) 
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 1 µl (1 U)                            T4 ligase- 1 µl (1 U)                          
Water- 10.02 µl     Water- 8.54 µl  
Self ligation control reaction  Undigested control 
reaction 
Vector – 1 µl (60 ng)    Vector – 1 µl (60 ng)   
Ligase buffer (10X) - 1.5 µl   Ligase buffer (10X) - 1.5 µl  
T4 ligase- 1 µl (1 U)      Water- 12.5 µl   
Water- 11.5 µl  
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All the ligation mixtures were incubated at RT for 4-5 h and 
transformed into DH5α competent cells as describedbefore. 
The positive clones were confirmed by restriction digestion using the 
protocol given below: 
2 µl (1µg) pcDNA3LuciFeExon4Ferase plasmid    
1 µl HindIII (1U) (New England Biolabs)  
1 µl XbaI (1U) (New England Biolabs)  
2 µl 10X buffer (New England Biolabs)  
14 µl Water   
2 µl (1µg) pcDNA3LuciFeExon4Ferase plasmid    
1 µl HindIII (1U) (New England Biolabs)  
1 µl XcmI (1U) (New England Biolabs)  
2 µl 10X buffer (New England Biolabs)  
14 µl Water 
 
2.19 Statistical analysis 
The Graph pad Prism package was used to analyse the data. Data was 
always represented as mean ± SD. P<0.05 were considered significant. 
Depending on experimental design, Student’s t-test, one-way and two-
way ANOVA with Bonferroni’s post-hoc comparison test were used and 
are indicated in the legends.  
 
 76 
AIM of the Thesis 
The aim of my PhD thesis was to investigate the effects of bilirubin on 
the DNA damage and DNA repair pathways. Previous studies showed 
the induction of oxidative stress as one of the mechanisms of bilirubin 
induced neurotoxicity.  
The first part of this thesis focused on the DNA damaging effect of 
bilirubin on neuronal cells. To this end, I investigated the time-
dependent effect of bilirubin-induced DNA damage and next, the 
involvement of oxidative stress on bilirubin-induced DNA damage. 
The second part of the thesis focused on the effects of bilirubin on 
double stranded-break repair pathways, using HeLa cell lines. In 
particular, I was interested to study time and dose-dependent increase in 
Homologous Recombination, mediated by bilirubin-induced oxidative 
stress. Furthermore, I investigated the effects of bilirubin on the NHEJ 
repair pathway. 
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Results 
3.1 Bf determination for in vitro experiments 
Bilirubin toxicity depends on the amount of Bf. Bf concentrations above 
70 nM are normally considered as toxic to human cells. In order to 
perform in vitro experiments with bilirubin, Bf was quantified using 
modified peroxidase assay as described in the Materials and Methods 
Section. 
Therefore, in order to perform in vitro experiments treating different cell 
lines with bilirubin, it was first required to prepare culture media (with 
10% or 15% fetal calf serum, FCS, depending on the cell type) 
containing different amounts of TB that leads to the desired Bf. 
Consequently, since different FCS stocks may have variations in both 
albumin concentration and its affinity for bilirubin, resulting in different 
Bf for the same theoretical FCS concentration, I determined the Bf for 
the stock of fetal calf serum utilized in all experiments done in the 
present thesis. 
The modified peroxidase assay involves minimum dilution of the 
sample, minimizing the effect of albumin dilution on binding affinity. 
This method is based on the fact that Bf gets oxidised to a colourless 
compound by peroxide, with first order kinetics; while albumin-bound 
bilirubin remains protected from oxidation. Bf determination was done 
with at least three (0.025-0.05 µg/ml) different enzymatic 
concentrations. Apparent Bf was calculated applying the formula given 
below, where Kp is the rate constant for the HRP enzyme used, ∆Abs 
corresponds to the change in absorbance over 30 seconds (Roca et al., 
2006). True Bf can be calculated from the apparent Bf by making a plot 
of 1/Apparent Bf vs HRP concentration used, where the“y intercept” of 
the plot corresponds to the real Bf. 
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Apparent Bf = ∆Abs/min/Kp x [HRP] 
 
Figure 10. Bf determination in two different types of culture media (DMEM 
with 10% FCS and EMEM/F12 with 15% FCS) by modified peroxidase assay. 
A). Bf determination in 10% FCS containing DMEM media. B). Bf determination in 
15% FCS containing EMEM/F12 media. X-axis corresponds to total bilirubin 
concentration while Y-axis corresponds to Bf concentration (this assay has been 
performed only once, as recommended by Prof. Tiribelli’s lab). 
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Using the modified peroxidase method, Bf was determined in DMEM 
media with 10% FCS and EMEM/F12 with 15% FCS (used to culture 
HeLa and SH SY 5Y cells respectively; Figure 10. Different molar 
ratios of bilirubin/albumin were used to calculate the Bf. 
3.2 Bilirubin-induced toxicity in immature neuronal (SH SY5Y) 
cells 
For bilirubin related studies of neurotoxicity, we used the SH SY 5Y 
cell line (Qaisiya et al., 2017a; Qaisiya et al., 2014). In order to check 
the cytotoxicity of bilirubin, SH SY 5Y cells were treated with 70 nM 
and 140 nM of Bf for different time intervals (1h, 4h and 24h). The 
MTT test was done to check the viability of cells in each of the 
respective time points. After one hour, viability was reduced to 91% and 
82% with 70 nM and 140 nM Bf, respectively. Viability was further 
reduced to 80% and 75% after 4h treatment with 70nM and 140 nM 
respectively. After 24h, viability with 70 nM treatment was 81%, while 
it was reduced to 69% in the case of 140 nM treatment (Figure 11). 
Viability at 140 nM compared to 70 nM showed a trend of decrease in 
viability at all time points studied. Based on our results and published 
data (Qaisiya et al., 2017a; Qaisiya et al., 2014), 140 nM Bf was chosen 
for subsequent studies to check bilirubin-induced DNA damage. 
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Figure 11. MTT test to check the viability of SH SY 5Y cells. SH SY 5Y cells 
were treated with 70 nM and 140 nM Bf for different time intervals ranging from 1h, 
4h and 24h. Cell viability was assessed using MTT reagent corresponding to 
respective time point. Viability of  untreated cells were considered as 100%. DMSO 
acts as a solvent for bilirubin and used as a control. Values are represented as mean 
± SD. ** represents P < 0.01; * P < 0.05; ns, non-significant. Two-way ANOVA 
with Bonferroni’s post hoc test was used to perform statistical analysis. 
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However, the cellular viability after bilirubin treatment could be 
confirmed by other well-known methods such as Lactate dehydrgenase 
(LDH) release, Caspase-3 cleavage Western blot and Annexin-
propidium iodide (PI) staining. MTT may not represents the appropriate 
assay to check cellular viability after bilirubin treatment due to the direct 
effect of bilirubin on mitochondria (Vaz et al., 2010). Because, MTT 
test directly measures the mitochondrial activity and bilirubin toxicity 
affects mitochondria (Rodrigues et al., 2000), measurement of cellular 
viability after bilirubin treatment by MTT test may result in an 
inaccurate value of cellular viability. 
 
3.3 Bilirubin-induced DNA damage in immature neuronal (SH SY 
5Y) cells 
Oxidative stress is one of the mechanisms involved in bilirubin-induced 
neuronal cell death. The accumulation of DNA damage due to bilirubin 
induced oxidative stress may play an important role in 
neurodegeneration. Accumulation of increased oxidative DNA damage 
in mitochondrial and nuclear DNA derived from post-martem brain 
regions of several neurodegenerative diseases tempted us to investigate 
the induction of DNA damage by bilirubin induced oxidative stress 
(Coppede and Migliore, 2015). In addition to oxidative base 
modifications, ROS can also create DSBs. The involvement of DSBs in 
neurodegeneration was first seen in AD during 1990s (Mullaart et al., 
1990).Similarly, human amyloid precursor protein (APP) trangenic 
mice, had increased neuronal DSBs than control mice (Suberbielle et al., 
2013). However, studying the contribution of DNA damage during 
neurodegeneration represents a complex question. It is not clear whether 
DNA damage cause neurodegeneration or it occurs as a consequence to 
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neurodegeneration. So, based on previous studies, we started to 
investigate the induction of DNA damage by bilirubin induced oxidative 
stress in immature neuronal cells. Since, immature neuronal cells 
represents the most severely affected cells in the brain due to high 
bilirubin levels (Bortolussi et al., 2012), induction of DNA damage by 
bilirubin induced oxidative stress may contribute to neuronal cell death 
by delayed cellular response to DNA damage such as apoptosis and 
senescence (Borges et al., 2008). 
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Figure 12. Western Blot analysis to check DNA damage induction by bilirbin. 
SH SY 5Y cells were treated with 140 nM bilirubin for different time intervals. 
DMSO acts as solvent for bilirubin and was added as control. A). Cells were 
harvested at different time intervals after bilirubin treatment and DNA damage was 
assessed by checking the level of 2AX using Western Blot. Graph in Panel C 
represents quantification from 3 independent experiments as shown in Panel A. B). 
P53 levels were checked in the same samples after bilirubin treatment using Western 
Blot analysis. Graphs in Panel D represents the quantification from 3 independent 
experiments as shown in Panel B.Values are represented as mean ± SD. * represents 
P < 0.05, ns represents non-significant. Student’s t-test was used to perform 
statistical analysis. 
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Phosphorylated H2AX (2AX) is the most commonly used marker to 
assess induction of double stranded DNA breaks and single stranded 
DNA accumulation generated during replication stress (Ward and Chen, 
2001). In response to ionizing radiation and DNA damage 
chemotherapeutic reagents, DSBs are generated that results in the rapid 
phosphorylation of H2AX (2AX) at Ser 139. The phosphoryaltion of 
H2AX is abudant, rapidly spread over the damaged chromatin that 
highly correlated with the number of DSBs, making it a good marker for 
double-stranded break and its repair  (Sharma et al., 2012). In addition, 
H2AX get phosphorylated by ATR in reponse to ssDNA formed during 
replication stress (Ward and Chen, 2001). Due to the phosphorylation of 
H2AX during DSBs and replication stress, it cannot be considered as a 
reliable marker specfically for DSBs. Another method that can be used 
to detect DNA damage in individual cells is the comet assay. This assay 
can be done under neutral and alkaline conditions. The comet assay 
done under alkaline conditions can detect single stranded breaks, double 
stranded breaks and alkali-labile lesions. Double stranded breaks can be 
detected specifically by neutral comet assay (Olive and Banath, 2006). 
However, comet assay was not performed in this thesis.  
In order to assess bilirubin-induced DNA damage by oxidative stress, 
SH SY 5Y cells were treated with 140 nM Bf for different time intervals 
ranging from 8h to 48h. Cells were harvested at the respective time 
points and the level of 2AX was determined by Western Blot analysis 
using 2AX-specific antibody.  
Bilirubin treatment leads to DNA damage induction, with an evident 
increase in the 2AX signal already after 24h of treatment. There was 
a time dependent increase in DNA damage in SH SY 5Y cells with 
maximum DNA damage at 48h after bilirubin treatment (4-5 folds) 
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(Figure 12A). Next, I checked the level of P53 to determine if it is 
activated after DNA damage induced by bilirubin. P53 activation after 
DNA damage could lead to a delay in cell cycle progresion to allow the 
repair of the damaged DNA. Alternatively, if the DNA damage is 
irreparable, cells could undergo apoptosis. Interestingly, P53 protein 
levels were not modulated after the induction of DNA damage by 
bilirubin (P53-DO-I Santa Cruz Biotechnology) (Figure 12B). 
 
 
3.4 Bilirubin-induced DNA damage is reversed by antioxidant 
treatment 
To demonstrate the involvement of oxidative stress in bilirubin induced 
DNA damage, cells were co-treated with N-Acetyl cysteine (NAC). 
NAC is the most commonly used antioxidant, which reduces oxidative 
stress by acting as a precursor of glutathione. In this set of experiments, 
SH SH 5Y cells were exposed to 140 nM Bf for different time intervals 
(8h, 24h, 30h and 48h). 
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Figure 13. Western Blot analysis to check DNA damage reversal by NAC 
treatment. SH SY 5Y cells were treated with 140 nM bilirubin for different time 
intervals (8-48h). DMSO acts as solvent for bilirubin and was added as control. For 
antioxidant (NAC) treatment, cells were pre treated with different doses of NAC for 
1h followed by co-treatment with bilirubin for 30h. A). DNA damage was assessed 
by checking the levels of 2AX using Western Blot. Graph represents the 
quantification from 2 independent experiments (Panel B). Values are represented as 
mean ± SD. * represents P < 0.05, ns represents non-significant. One-way ANOVA 
Bonferroni's post hoc test was used to perform statistical analysis. 
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In the case of the NAC treatment experiment, to determine the role of 
oxidative stress in bilirubin-induced DNA damage, the experimental 
time-point of 30 h of bilirubin exposure was selected. In this 
experiment, cells were exposed to different doses of NAC for 1h 
followed by co-treatment with bilirubin for 30h. As shown in Figure 13, 
bilirubin treatment led to time-dependent increase in DNA damage 
(compare DMSO with Bil 8h-48h). The level of P53 remained 
unaffected after bilirubin treatment confirming the results of Figure 12B. 
However, when cells were co-treated with NAC, bilirubin-induced DNA 
damage was reversed by the treatment in a dose dependent manner 
(compare Bil 30h with Bil 30h + 0.1 mM NAC, Bil 30h + 0.3 mM 
NAC, and Bil 30h + 0.4 mM NAC). This result strongly suggests the 
involvement of oxidative stress in bilirubin induced DNA damage. 
 
3.5 Bilirubin-induced DNA damage foci decreased after NAC 
treatment 
In order to confirm the Western Blot analysis results, 
immunofluorescence analysis was done to detect the 2AX foci 
formation after bilirubin treatment. In these experiments, SH SY 5Y 
cells were pre-exposed with NAC for 1h followed by co-treatment with 
bilirubin for 30h as described in the previous experiment (Figure 13). 
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Figure 14. Immunofluorescence analysis to check bilirubin induced DNA 
damage reversal by NAC treatment. SH SY 5Y cells were treated with 0.4 mM 
NAC for 1h followed by co-treatment with bilirubin for additional 30h. A). 
Immunofluorescence analysis was done to check the presence of DNA damage foci. 
Graph represents the quantification from 2 independent experiments (Panel B). 
Values are represented as mean ± SD. * represents P < 0.05. One-way ANOVA 
Bonferroni 's post hoc test was used to perform statistical analysis. Scale bar 
represents 30 µM. 
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Treated cells were fixed, permeabilized and stained with an anti 
2AX-specific antibody. As shown in Figure 14, bilirubin treatment 
led to a significant increase in 2AX foci formation in cells (P < 0.05-
One Way ANOVA). Co-treatment with NAC reversed the DNA damage 
as shown by reduced 2AX foci formation in NAC co-treated cells. 
The immunofluorescence results along with the Western Blot result in 
Figure 13, demonstrated the involvement of oxidative stress in bilirubin-
induced DNA damage. 
 
3.6 Bilirubin-induced toxicity in HeLa DR GFP cells 
To investigate the role of bilirubin in HR, we took advantage of the 
HeLa DR GFP stable cell line. These cells contain a single copy of a 
homologous recombination reporter construct (an inactive GFP gene 
plus a duplicated, truncated, GFP fragment) inserted in the genome (see 
section 1.9.3). Transfection of these cells with a plasmid encoding the 
Isce1 restriction enzyme leads to the generation of a DSB in the 
upstream inactive GFP fragment. DSB formation activates HR between 
the upstream inactive version of GFP and the downstream truncated 
GFP, resulting in a full length, wild-type, GFP cDNA. The total number 
of GFP positive cells after FACS analysis corresponds to cells that have 
undergone HR (Cuozzo et al., 2007).  
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Figure 15. MTT test to check the viability of HeLa DR GFP cells. HeLa DR GFP 
cells were treated with 140 nM Bf for different time intervals ranging from 1h, 4h 
and 24h. Cell viability was assessed using MTT reagent corresponding to respective 
time point. Viability of untreated cells were considered as 100%. DMSO acts as a 
solvent for bilirubin and used as a control. Values are represented as mean ± SD. ** 
represents P < 0.01, *** represents P < 0.001. Two way ANOVA with Bonferroni’s 
post hoc test was applied to perform statistical analysis. 
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HeLa DR GFP cells were exposed to bilirubin from 1h to 24h. Cell 
viability was assessed by the MTT test at the different time points. 
Treatment with 140 nM bilirubin led to 30% reduction in cellular 
viability after 1h and 4h of treatment. The effect of bilirubin became 
more severe after 24h of treatment, with 60% reduction in cellular 
viability (Figure 15).  
Based on these observations, 140 nM Bf was used to do further 
experiments. However, in the dose-response experiments lower doses 
were also used in order to find the optimal Bf concentration that can 
modulate homologous recombination. 
 
3.7 Time-course effect of Bilirubin on HR 
The HeLa DR GFP stable cell line was used to study the effects of 
bilirubin on homologous recombination. In this experiment, HeLa DR 
GFP cells were transfected with the Isce1 plasmid and bilirubin was 
added for different time points ranging from 24-66h. The IsceI plasmid 
codes for the IsceI endonuclease, which generates a DSB in the reporter 
construct, resulting in the reconstitution of the GFP open reading frame 
after homology directed repair (Cuozzo et al., 2007). Cells were 
analysed for GFP fluorescence by FACS analysis 72h after transfection. 
As shown in Figure 16, bilirubin treatment followed by Isce1 
transfection led to a trend towards time-dependent increase in GFP 
positive cells. Interestingly, bilirubin itself did not stimulate the 
homologous recombination (compare UT and UT+Bil in FACS raw 
data, Figure 16, Panel B). However, in the presence of double stranded 
breaks, bilirubin treatment led to time dependent increase in the number 
of GFP positive cells,clearly suggesting the modulation of HR by 
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bilirubin (compare Isce1 DMSO and Isce1 Bil treatments, Figure 16, 
Panels B& C). Since transfection efficiency was normalised with the 
transfection efficiency of a different well, existence of lot of variability 
results in non-significant difference between different conditions when 
analysed using One-way ANOVA. 
 
3.8 Dose-response effect of Bilirubin on HR 
To determine the optimal dose of bilirubin resulting in an increase in 
HR, HeLa DR GFP cells were treated with bilirubin ranging from 10 
nM to 140 nM for 66h after co-transfection with the Isce1-coding 
plasmid and a second plasmid encoding for renilla luciferase, which was 
used as control for transfection efficiency.  
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Figure 16. Time course effect of bilirubin on Homologous Recombination. HeLa 
DR GFP cells were transfected with plasmid encoding Isce1. After 6-7h of 
transfection, 140 nM Bf was added to cells for different time intervals ranging from 
24-66h. DMSO acts as solvent for bilirubin and was added as control. Cells were 
analysed for GFP fluorescence by FACS analysis 72h after transfection (Panel B). 
Panel C, represents quantification from 2 independent experiments. eGFP in parallel 
well was used to normalise for differences in transfection efficiency. Every 
condition was done in duplicates in each experiment. Values are represented as  
mean ± SD.  ns represents non-significant. One-way ANOVA Bonferroni 's post hoc 
test was used to perform statistical analysis. 
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Figure 17. Dose response effect of bilirubin on Homologous recombination. 
HeLa DR GFP cells were co-transfected with plasmid encoding Isce1 (pCBA Isce1) 
and renilla (pHRG TK Renilla). After 6-7h of transfection, different doses of Bf (10-
140 nM) was added to cells. DMSO acts as solvent for bilirubin and was added as 
control. Cells were analyzed for GFP expression by FACS analysis 72h post-
transfection (Panel B). Panel C, represents quantification from 3 independent 
experiments. Panel D shows the effect of DMSO on HR. Data was normalised to 
renilla activity corresponds to same well. Values are represented as  mean ± SD. *** 
represents P < .001, ** represents P < .01, * represents P < .05 and ns represents 
non-significant. One-way ANOVA with Bonferroni’s post hoc test was done to 
perform the statistical analysis.  
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In this strategy, the percentage of GFP cells in a particular well was 
normalised with the transfection efficiency of the same well. In Figure 
16, data was normalised to the transfection efficiency corresponds to a 
parallel well. Thus, the data obtained after normalisation may present 
higher variabiltiy, as can be seen in the bar graph. In this experiment, 
transfected cells were collected 72h after transfection, and half of the 
cell suspension was used to determine the transfection efficiency by 
measuring renilla luciferase activity, and the other half analysed for GFP 
expression by FACS analysis (Figure 17). I observed a dose-dependent 
increase in HR starting at 40 nM, with maximum increase at 140 nM 
(Figure 17, Panel B& C). Panel D in Figure 17 shows the effect of 
DMSO on HR. Bilirubin addition leads to significant increase in HR 
(compare Isce1 DMSO and Isce Bil), as observed in Panels B and C. 
DMSO addition does not result in DNA damage and, it apparently 
results in a significant decrease in HR (compare Isce1 DMSO and 
Isce1). This result confirm that the effect observed in Panel B is not due 
to the effect of DMSO on HR. 
 
3.9 Bilirubin-induced HR is reversed after treatment with NAC 
In order to demonstrate the role of oxidative stress behind bilirubin-
induced modulation in HR, HeLa DR GFP cells were transfected with 
the Isce1-coding plasmid and a second plasmid encoding for renilla, 
which was used as control for transfection efficiency. 
Cells were pre-exposed with 2 mM NAC for 1h followed by co-
treatment with 140 nM Bf for 66 h. Fresh NAC was added to the culture 
media after every 24 h. Cells were analyzed for GFP fluorescence by 
FACS analysis 72 h after transfection. As shown in Figure 18, bilirubin 
treatment led to an increase in GFP positive cells, confirming the results 
3 RESULTS 
 
98 
of Figure 17. However, co-treatment with NAC reduced the proportion 
of GFP positive cells, strongly suggesting the involvement of oxidative 
stress behind bilirubin induced modulation of HR. 
 
3.10 Bilirubin does not alter cell cycle profile of HeLa DR GFP cells 
Bilirubin-induced oxidative stress might affects the cell cycle of HeLa 
DR GFP cells. To investigate cell cycle of HeLa DR GFP cells, they 
were treated with bilirubin for 48h and cell cycle was analyzed.  
Cell cycle analysis was performed in the HeLa DR GFP cells, with no 
perturbation in any phase of cell cycle by quantification of DNA content 
using different DNA binding dyes (Propidium Iodide) by FACS 
analysis. It is one of the most commonly method used to analyse the cell 
cycle profile of any living cell. These DNA dyes bind stoichiometrically 
to the DNA i.e. according to the amount of DNA present in the cells. 
Cells that are in S phase have more DNA than cells in G1, will take up 
proportionally more dye and will fluoresce more brightly until they have 
doubled their DNA content. The cells in G2 will be approximately twice 
as bright as cells in G1. As seen in Figure 19 (Panel A & B), treatment 
with bilirubin had no apparent effect on any phase of cell cycle, in 
contrast to a previous study done in SH SY 5Y cells (Deganuto et al., 
2010). 
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Figure 18. Effect of antioxidant (NAC) treatment on bilirubin induced 
Homologous recombination. HeLa DR GFP cells were co-transfected with plasmid 
encoding Isce1 (pCBA Isce1) and renilla (pHRG TK Renilla). After 6-7h of 
transfection, 140 nM Bf was added to cells. DMSO acts as solvent for bilirubin and 
was added as control. In the case of NAC treatment, cells were pretreated with 2mM 
NAC for 1h before bilirubin treatment followed  by co-treatment along with 
bilirubin. Fresh NAC was added every 24h. Cells were analyzed for GFP expression 
by FACS analysis 72h post-transfection (Panel C). Panel B, represents quantification 
from 3 independent experiments. Data was normalised to renilla activity 
corresponds to same well. Each condition was done in duplicate. Values are 
represented as  mean ± SD. *** represents P < 0.001. One-way ANOVA  with 
Bonferroni’s post hoc test was applied to perform statistical analysis. 
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Figure 19. Cell cycle analysis of HeLa  DR GFP cells after bilirubin treatment. 
HeLa DR GFP cells were treated with 140 nM Bf for 48h. DMSO acts as solvent for 
bilirubin and was added as control. Cell cycle analysis was done using Propidium 
Iodide (PI) staining (Panel A). Graph represents quantification from 3 independent 
experiments (Panel B). 
 
3 RESULTS 
 
101 
3.11 Bilirubin induces DNA damage in HeLa cells 
Based on the findings from our previous results, here we determined the 
presence of DNA damage by measuring the levels of 2AX by 
Western Blot analysis in HeLa DR-GFP cells after bilirubin treatment. 
In these experiments, HeLa DR GFP cells were transfected with Isce1 
plasmid and bilirubin was added after 6h. Cells were harvested 72h after 
transfection and DNA damage was assessed by assessing the levels of 
2AX.  
As can be seen in Figure 20, treatment with bilirubin led to DNA 
damage in HeLa DR GFP cells. These results further confirmed our 
previous results in Figure 12-14.  
 
3.12 Bilirubin induces DNA damage foci formation in HeLa cells 
I further confirmed the bilirubin-mediated increase in DNA damage in 
HeLa cells by immunofluorescence analysis. During DNA damage, 
phosphorylated 2AX form DNA damage foci in the nucleus which 
could be detected by IF with the anti phosphorylated 2AX antibody. 
As can be seen in Figure 21, bilirubin treatment led to increase in the 
number of cells having more than ten 2AX foci, thus, confirming our 
Western Blot result from Figure 20. 
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Figure 20. Bilirubin induced DNA damage in HeLa DR GFP cells. HeLa DR 
GFP cells  were transfected with plasmid encoding Isce1 (pCBA Isce1). After 6-7h 
of transfection, 140 nM Bf was added to cells. DMSO acts as solvent for bilirubin 
and was added as control. Cells were harvested 72h after transfection and DNA 
damage was assessed by checking the level of 2AX (panel A). Graph in panel B, 
represents quantification from three independent experiments and statistical analysis 
was done using One-way ANOVA with Bonferroni’s post hoc test. Values are 
represented as mean ± SD. * represents P < 0.05. 
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Figure 21. Bilirubin induced DNA damage foci formation in HeLa DR GFP 
cells. HeLa DR GFP cells cells were transfected with plasmid encoding Isce1 
(pCBA Isce1). After 6-7 hours of transfection, 140 nM Bf was added to cells. 
DMSO acts as solvent for bilirubin and was added as control. Immunofluorescence 
analysis was done after 72h to check the presence of H2AX foci. Values are 
represented as mean ± SD. Graph in panel B, represents quantification from two 
independent experiments and statistical analysis was done using One- way ANOVA 
with Bonferroni’s post hoc test. * represents P  < 0.05, ** represents P  < 0.01. Scale 
bar represents 30 µM. 
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3.13 Bilirubin modulates the NHEJ pathway in HeLa cells 
In order to determine whether bilirubin may also modulate NHEJ, which 
is another pathway that can get activated after DNA damage. In order to 
study NHEJ , I have used the pIM EJ5-GFP plasmid, as described in 
Section 1.9.5.  
This plasmid consists of a promoterless GFP fragment preceded by a 
puromycin resistant cassette. A promoter is present upstream of the 
promycin resistance cassette. Two Isce1 site flank the puromycin 
cassette. Due to the absence of the promoter immediate upstream of 
GFP fragment, this plasmid does not express the GFP protein.  
Isce1 enzyme induced breaks at the two Isce1 sites stimulates NHEJ 
followed by restoration of GFP expression. In this experiment, HeLa 
cells were co-transfected with the NHEJ substrate vector (pIM EJ5-
GFP), a plasmid encoding Isce1 and a plasmid encoding renilla 
luciferase (pHRG-TK Renilla-transfection efficiency control). The 
pCBA plasmid was used as negative control.  
Bilirubin was added 6-7h after transfection and cells were analysed for 
GFP fluorescence by FACS analysis 72h after transfection. Isce1 
transfection led to significant increase in the number of GFP positive 
cells, suggesting the activation of NHEJ by Isce1-induced DSBs. 
However, addition of bilirubin significantly increased the number of 
GFP positive cells suggesting the activation of NHEJ by bilirubin. 
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Figure 22. Effect of Bilirubin on Non-Homologous End Joining (NHEJ). HeLa 
cells were co-transfected with pIM EJ5-GFP plasmid, plasmid encoding Isce1 
(pCBA Isce1) and renilla plasmid (pHRG TK-renilla). After 6-7h of transfection, 
140 nM Bf was added to cells. DMSO acts as solvent for bilirubin and was added as 
control. Cells were analysed for GFP expression 72 after transfection (Panel B). 
Panel C, represents quantification from 2 independent experiments. Data was 
normalised using renilla activity corresponding to same well. Values are represented 
as mean ± SD.** represents P <0.01, * represents P <0.05. One-way ANOVA 
Bonferroni 's post hoc test was used to perform statistical analysis. 
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3.14 Effect of bilirubin on etoposide induced DNA damage. 
Based on our previous results on bilirubin induced modulation of HR 
and NHEJ, we wanted to investigate the effect of bilirubin on DNA 
damage induced by a strong DNA damaging reagent, Etoposide. 
Etoposide acts by binding to DNA and DNA topoisomerase II, thereby 
inhibiting DNA re-ligation and causing DNA breaks. In this 
experiments, cells were pre-exposed with 140 nM of  Bf for 24 h. After 
24 h, bilirubin was removed and 100 µM etoposide was added for 2 h. 
After 2 h, etoposide was removed and fresh bilirubin was added for 
different time intervals ranging from 0-48 h. Cells were harvested at 
respective time intervals and the presence of DNA damage was 
investigated by checking the levels of 2AX. As can be seen in Figure 
23, addition of etoposide leads to extensive DNA damage (compare 
Lanes 2 and 3). The etoposide induced DNA damage  repaired by cell 
over time up to 6 h (Lane 5). However, DNA damage started to 
accumulate after 24h of etoposide release, most probably due to the 
arrest of the cells in the G2/M phase (Schonn et al., 2010). However, 
when  the same cells were treated with bilirubin after etoposide release, 
there was no accumulation of DNA damage at later time points 
(Compare lane 6-7 with lane 12-13). The reduced accumulation of DNA 
damage after bilirubin treatment may be due to completely different 
effect of bilirubin and etoposide on the cell cycle. Another possible 
reason of reduced accumulation of DNA damage in bilirubin treated 
cells may be due to repair of DNA breaks by bilirubin-induced 
modulation of DNA repair pathways. However, we did not followed this 
experiment further. 
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Figure 23. Effect of bilirubin on etoposide induced DNA damage. HeLa cells 
were treated with 140 nM Bf for 24h. After 24h, cells were treated with 100 µM 
etoposide for 2h. Etoposide was released from the cells and fresh bilirubin was 
addded for different time intervals. DNA damage analysis was done by cheking the 
level of 2AX. 
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3.1 TALEN mediated correction of UGT1 KO mice 
Our lab had generated several TALEN pairs targeting different 
restriction sites in the mutated Exon4 (mExon4) of the Ugt1 KO mice. 
This particular type of approach overcame the presence of allele specific 
single nucleotide polymorphisms (SNPs) and a pseudogene. Both these 
conditions restrict the use of surveyor assay for INDELs detection. In 
this work, the NcoI restriction site targeting TALEN pair was shown to 
be most active (Porro et al., 2014).  
In this part of thesis, we decided to correct the endogenous mUgt1 locus 
by employing NcoI restriction site targeting TALEN. With the aim of 
correcting the one-base pair deletion at the exon 4 of the Ugt1 locus, 
mice were injected with the AAV virions expressing the TALEN pairs 
targeting the NcoI restriction site, along with the donor template as done 
before (Bedell et al., 2012). Our previous attempts to correct the 
endogenous loci by injecting 3 different Adeno-associated viruses 
(AAV) packaged with the right arm of TALEN, the left arm of TALEN 
and the donor template containing the corrected version of Exon 4 
flanked by homology arms failed.  
We decided to generate a new codon optimised AAV donor vector in 
order to eliminate cryptic splicing site that were present in the previous 
AAV donor vector construct. To generate the new pAAV donor vector, 
a DNA fragment containing the new codon optimised Exon 4 and 
flanking introns was syntesized and cloned into the pUC57 plasmid by a 
company. The pUC57 codon optimized Exon 4 plasmid was digested 
with BamH1 enzyme in order to release the insert (Figure 24B). The 
released Exon 4 fragment was cloned directly into the pBK plasmid 
without any purification step, since both plasmids have different 
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antibiotic resistance. Three different pBK codon optimised Exon 4 
plasmids were screened by digestion with the BamH1 restriction 
enzyme. Only one clone out of 3 was positive for the presence of the 
correct insert (Figure 24C). Next, the new pAAV donor vector was 
generated from the old pAAV donor, after removal of Exon 4 from the 
pAAV old donor plasmid by BamHI digestion (Figure 24D). The 
plasmid vector backbone was directly ligated without purification step 
with codon-optimised Exon4 derived from PBK codon optimised Exon 
4. After restriction digestion with NcoI, only one clone (Clone 7) gave 
the expected size of restriction fragments (4278, 1258, 1179, 95, and 30 
bp; Figure 24E).  
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Figure 24. Sub-cloning of new codon optimised Exon 4 to generate the AAV 
donor vector. A). Strategy showing sub-cloning of codon-optimised Exon4 into the 
AAV vector. B). Restriction digestion of pUC57 containing the codon-optimised 
Exon4 with BamHI, for cloning the codon-optimised Exon4 into the BamHI-
digested PBK vector.C). Restriction digestion of different clones of PBK-Exon4 
with BamHI. D). Restriction digestion of old pAAV donor with BamH1 enzyme in 
order to replace the old Exon4 with codon optimised Exon4 to generate the new 
donor. E). Restriction digestion of different clones of pAAV new donor with NcoI.  
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Figure 25. Orientation check of new AAV vector. The new pAAV donor vector 
clone 7 was digested with SacI restriction enzymes to give different size of 
restriction fragments.  
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Next, the sense orientation of pAAV new donor vector clone 7 was 
confirmed by SacI digestion (Figure 25). The pAAV new donor vector 
has three SacI restriction sites present at different locations in the 
plasmid. The digestion of pAAV new donor plasmid with sense 
orientation should give 3 different restriction fragments (5481, 763, 576 
bp). This particular restriction digestion confirmed the sense-orientation 
of clone 7.  
We also wanted to check the activity of the NcoI targeting TALEN pairs 
in vivo by injecting them into wild type mice. Genomic DNA was 
isolated from the liver of injected mice and genomic PCR was done 
using specific primers as shown in Figure 4A-B. Genomic PCR 
generated a PCR product of 1020 bp.  
Genomic DNA from Ugt1 KO animals were used as a control to check 
the specificity of primers pairs and to exclude the amplification of the 
Ugt1 psedudogene, as discovered in our previous study (Porro et al., 
2014). This PCR analysis showed that the primer pairs used in this PCR 
analysis are amplifying only the Ugt1 locus, and not the pseudogene 
(Figure 26C). The genomic PCR product was subjected to NcoI 
restriction digestion (Figure 26D) in order to detect fragments resistant 
to NcoI digestion, indicating NHEJ repair and mutation of the NcoI site. 
However, after repeated analysis of PCR analysis and restriction 
digestion, no NcoI resistant bands were seen. These results were non-
conclusive. However, we do not have any information regarding 
expression of TALEN pairs in vivo. 
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Figure 26. TALEN activity analysis by genomic PCR and restriction digestion. 
A)Schematic diagram showing NcoI restriction site in Exon4 of Ugt1 locus. The 
TALEN binding site flanking the NcoI restriction site is also shown. B). Schematic 
diagram showing the strategy used to check TALEN activity. C). Genomic PCR 
analysis showing amplification of Ugt1 Exon4 locus. The PCR product was 
separated in 1% agarose gel D). The genomic PCR product was then digested with 
NcoI restriction enzyme and the resulting product was separated in 1% agarose gel.  
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Next, we decided to modify the strategy and to use the Staphylococcus 
aureus CRISPR/Cas9 platform. This approach requires the 
administration of two AAV vectors (instead of the three AAVs required 
with the TALEN strategy), one containing the SaCas9 and the sgRNA, 
and the other one with the donor DNA, which should result in higher 
efficiency. We designed 4 difference gRNA targeting the Exon 4 of the 
Ugt1 gene locus and cloned them into the S aureus pX601 Cas9 vector. 
The clones positive for the presence of each gRNA were confirmed by 
sequencing analysis. In order to check the activity of each gRNA, a 
single stranded annealing (SSA) reporter was utilized. This reporter 
consists of luciferase gene interrupted by the Exon 4 derived from the 
Ugt1 gene locus. The Exon4 is flanked by direct repeated regions 
obtained from the luciferase gene. Induction of DSB at Exon 4 using 
site-specific nuclease stimulates recombination between the direct 
repeats, restoring luciferase activity, consequently loosing the Exon 4 
(Figure 27A). In order to check the activity of different gRNAs, Hep3B 
cells were co-transfected with the SSA reporter vector, different 
concentrations of gRNAs and pHRG-Tk renilla plasmid. The cells were 
harvested 48 h after transfection and luciferase activity was measured 
using a luminometer. There was a dose-response increase in activity of 
all the gRNAs. Interstingly, the NcoI-TALEN pair was always more 
active than all the 4 gRNAs (Figure 27).  
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Figure 27. gRNA activity analysis in Hep3B cell line using  a single stranded 
annealing (SSA) vector. A) Schematic diagram showing SSA vector used to check 
the activity of site-specific nucleases. B) This figure is showing the location of 4 
different gRNAs targeting mUgt1 Exon4. C) The gRNA activity analysis after co-
transfecting Hep3B cells with SSA vector, different concentrations of gRNAs and 
pHRG-Tk renilla vector. Data was normalised for transfection efficiency using 
renilla activity corresponds to same well. NcoI targeting TALEN pairs were used as 
positive control. ANOVA test with Bonferroni’s correction was done to perform 
statistical analysis. *** represents P<0.001.  
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Next, activity of each NcoI targeted TALEN pair was determined using 
the SSA reporter. Hep3B cells were co-transfected with the SSA 
reporter vector, different concentrations of NcoI targeting TALEN pair 
and pHRG-Tk renilla plasmid. The cells were harvested 48h after 
transfection and luciferase activity was measured using a luminometer. 
There was a dose-response increase in activity of TALEN pairs (Figure 
28).  
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Figure 28. NcoI TALEN activity analysis in Hep3B cell line using a single 
stranded annealing (SSA) vector. A) Schematic diagram showing SSA vector used 
to check the activity of TALENs. B) This figure is showing the activity of TALENs 
using SSA vector after transecting different amount of TALEN pairs. Data was 
normalised for transfection efficiency using renilla activity corresponds to same 
well. ANOVA test with Bonferroni’s correction was done to perform statistical 
analysis. *** represents P<0.001, ** represents P<0.01. ns represents non-
significant.  
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3.2 Stable clone generation for miRNA screening 
Different endonucleases such as TALEN and CRISPR/Cas9 system 
have been used to increase the frequency of HR. Although, 
endonuclease technology significantly increases HR, novel techniques 
are required to further increase the HR rate when used in combination 
with different endonucleases. We decided to perform a miRNA 
screening to find miRNA modulating HR. We planned to generate a 
stable Flp-IN Hek293 SSA reporter cell line. Two different types of 
stable clones were planned to be generated: the first one containing 
pcDNA5 Luc construct integrated, and the second one with the 
pcDNA5LuciFeExon4Ferase construct integrated. Both constructs were 
initially cloned in a pGL3 vector. For the purpose of Flp-IN stable clone 
generation, both the constructs were sub-cloned into the pcDNA5/FRT 
vector (Figure 29 & 30). 
3.2.1 Subcloning of Luciferase and LuciFeExon4Ferase into 
pcDNA5/FRT plasmid 
First, I sub-cloned the luciferase construct from the pGL3 luciferase 
vector into the pcDNA5/FRT plasmid, as shown in Figure 29A. The 
pGL3 Luciferase vector was digested with HindIII+ XbaI to release the 
1651 bp fragment (Figure 29B). This fragment was then directly cloned 
into the pBK vector without purification step. The presence of the 
luciferase insert in the pBK plasmid was confirmed by HindIII+XbaI 
digestion (Figure 29C). Overall, 6 different plasmids were positive for 
the presence of luciferase. The luciferase insert obtained from the 
positive clone 2 was then ligated into the pcDNA5/FRT plasmid. The 
presence of the Luciferase gene in the pcDNA5/FRT plasmid was 
confirmed by HindIII+ PstI and HindIII+ SpeI restriction digestion. 
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Overall, 3 different plasmid were positive from all the screened 
plasmids (Figure 29D). 
Next, I sub-cloned the luciFeExon4Ferase fragment using the strategy 
shown in Figure 30A. The pGL3 luciFeExon4Ferase was designed 
previously in our lab (Porro et al., 2014). The pGL3 luciFeExon4Ferase 
vector was digested with HindIII+ XbaI to release the 2967 bp fragment 
(Figure 30B). This fragment was directly cloned into the pBK vector 
without purification step. The presence of luciFeExon4Ferase insert in 
the pBK plasmid was confirmed by HindIII+XbaI digestion (Figure 
30C). 
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Figure 29. Sub-cloning of luciferase construct into pcDNA5/FRT plasmid. A). 
Strategy showing sub-cloning of the luciferase construct from pGL3 luciferase 
vector into the pcDNA5/FRT plasmid. B). Restriction digestion of pGL3 control 
vector. C). Restriction digestion of isolated clones to confirm the presence of the 
luciferase insert in the PBK plasmid. D). Restriction digestion of isolated clones to 
confirm the presence of luciferase insert in the pcDNA5/FRT plasmid. 
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Figure 30. Sub-cloning of luciFeExon4Ferase construct into pcDNA5/FRT 
plasmid. A). Strategy showing sub-cloning of construct from pGL3 
luciFeExon4Ferase vector into the pcDNA5/FRT plasmid. B). Restriction digestion 
of pGL3 luciFeExon4Ferasevector. C). Restriction digestion of isolated clones to 
confirm the presence of the LuciFeExon4Ferase fragment in the PBK plasmid. D). 
Restriction digestion of isolated clones to confirm the presence of the 
LuciFeExon4Ferase insert in the pcDNA5/FRT plasmid. 
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Overall, 4 different plasmids were positive for the presence of the 
luciFeExon4Ferase fragment. The luciFeExon4Ferase construct 
obtained from positive clone 2 was then cloned into the pcDNA5/FRT 
plasmid. The presence of luciFeExon4Ferase gene in the pcDNA5/FRT 
plasmid was confirmed by HindIII+ XcmI and BamHI restriction 
digestion. Overall, 2 different plasmids were positive from all the 
screened plasmid (Figure 30D). 
 
3.2.2 Stable clone generation 
As discussed above, we planned to generate Hek293 Flp-IN stable cell 
line for miRNA screening. However, we realised that Hek293 cells 
could not be used for miRNA screening because they get detached very 
easily from the wells during the automatic washing of the cells 
performed during the screening, by high-throughput screening facility. 
So, we decided to make the required stable clones in the Hep3B liver 
cell line, which do not detach during harsh washings. Since the Flp-IN 
system is not available in any liver cell line, we decided to generate the 
cell lines by transfection of the plasmids followed by selection, a 
procedure that is based on the random integration of the plasmids in the 
Hep3B genome. 
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Figure 31. Hep3B luciferase stable clone generation. A). Strategy showing 
generation of Hep3B luciferase stable clone. B). Graph showing the normalised 
luciferase activity in different stable clones obtained. Hep3B cells transfected with 
pcDNA5 Exon4 plasmid acts as positive control in this experiment. 
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In order to generate Hep3B luciferase stable clones, cells were co-
transfected with the pcDNA5Luciferase and pBABE plasmids. The 
pBABE plasmid was co-transfected in order to select the stable clones 
with the antibiotic geneticin, since pcDNA5/FRT plasmid does not 
contain any antibiotics resistance gene for selection.After selection for 
10 days, different colonies were obtained, expanded and luciferase 
activity was checked in the different clones. From 9 stable clones, clone 
1 has the highest luciferase activity followed by clone 3, clone 5 and 
clone 7 (Figure 31).  
Next, we generated Hep3B luciFeExon4Ferase stable clones. To 
generate luciFeExon4Ferase stable clones, cells were co-transfected 
with pcDNA5 lucFeExon4Ferase and pBABE plasmid. After selection 
for 10 days, different colonies obtained were expanded and luciferase 
activity was checked in different clones after transfecting them with 
NcoI restriction site targeting TALEN pair. Among 11 clones obtained, 
clone 10 expressed the highest luciferase activity followed by clone 5 
and clone 11. Although, clone 10 expresses the highest induction of 
luciferase activity after TALEN transfection, the presence of basal 
luciferase activity in untransfected cells may represent the 
intrachromosomal recombination due to integration of plasmid at 
several different locations in the genome (Figure 32).  
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Figure 32. Hep3B lucFeExon4Ferase stable clone generation. A). Strategy 
showing generation of Hep3B lucFeExon4Ferase stable clone. B). Graph showing 
the normalised luciferase activity in different stable clones obtained after 
transfection with NcoI restriction site targeting TALEN pair and pHRG TK renilla 
plasmid. Hep3B cells co-transfected with pcDNA5 Exon4 plasmid, NcoI restriction 
site targeting TALEN pair and pHRG TK renilla plasmid acts as positive control in 
this experiment. Data was normalised to renilla activity corresponds to the same 
well. Student t-testwas done to perform statistical analysis. * represents P<0.05, ** 
represents P<0.01, *** represents P<0.001, ns represents non-significant. 
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3.2.3 Cloning of luciferase and luciFeExon4Ferase in pcDNA3 
The absence of mammalian antibiotic resistance in the pcDNA5/FRT 
plasmid forced us to clone the luciferase and luciFeExon4Ferase in the 
pcDNA3 vector, which contains the geneticin resistance gene.  
In order to clone the luciferase construct in the pcDNA3 plasmid, the 
pBK luciferase plasmid from Figure 7 was utilized. The pBK luciferase 
construct was digested with HindIII+ XbaI to release the luciferase 
gene. The luciferase gene was then directly ligated into HindIII+XbaI 
digested pcDNA3 vector without purification step. The presence of the 
luciferase construct in pcDNA3 plasmid was confirmed by 3 different 
types of restriction digestions as shown in Figure 33.  
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Figure 33. Sub-cloning of luciferase construct into pcDNA3. A). Strategy 
showing sub-clonng of luciferase construct from PBK luciferase contruct into 
pcDNA3 plasmid. B). Restriction digestion of final pcDNA3 luciferase plasmid with 
different restriction enzymes.  
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In order to clone the LuciFeExon4Ferase construct in the pcDNA3 
plasmid, the pBK LuciFeExon4Ferase plasmid from Figure 8 was 
utilized. The pBK LuciFeExon4Ferase construct was digested with 
HindIII+ XbaI to release luciferase gene. The LuciFeExon4Ferase gene 
was than directly ligated into HindIII+XbaI digested pcDNA3 vector 
without purification step. The presence of the LuciFeExon4Ferase 
construct in pcDNA3 plasmid was confirmed by 3 different type of 
restriction digestion as shown in Figure 34.  
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Figure 34. Sub-cloning of luciFeExon4Ferase construct into pcDNA3. A). 
Strategy showing sub-cloning of luciFeExon4Ferase construct from PBK 
luciFeExon4Ferase construct into pcDNA3 plasmid. B). Restriction digestion of 
final pcDNA3 luciFeExon4Ferase with different restriction enzymes.  
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Stocker and coworkers showed the beneficial and antioxidant properties 
of bilirubin at mildly elevated concentrations (Stocker et al., 1987). 
Conversely, elevated concentrations of bilirubin are responsible for the 
generation of oxidative stress. Increased oxidative stress leads to 
elevated synthesis of glutathione by cells (Giraudi et al., 2011). This 
study also proved that oxidative stress is a major determinant of 
bilirubin-induced neurotoxicity. Similarly, several in vitro and in vivo 
studies, including ours, have shown, induction of oxidative stress by 
bilirubin (Bortolussi et al., 2015; Brito et al., 2004; Cesaratto et al., 
2007; Daood et al., 2012; Deganuto et al., 2010; Oakes and Bend, 2005; 
Seubert et al., 2002).  
The present thesis work shows the effect of bilirubin on DNA damage 
and repair pathways, using two different cell line models (SH SY 5Y 
and HeLa). This work also showed the direct involvement of oxidative 
stress in DNA damage, and activation of HR and NHEJ.  
 
4.1 Bilirubin induced DNA damage 
In this study, bilirubin cytotoxicity was investigated in the 
neuroblastoma SH SY 5Y cell line after treatment with a clinically 
relevant Bf concentration, as reported in neonates with bilirubin 
encephalopathy (Ostrow et al., 2003). In vivo studies in Ugt1 KO mice 
showed immature Purkinje cells being the most severely affected  in the 
cerebellum due to bilirubin toxicity (Bortolussi et al., 2014a). SH SY 5Y 
cells were used in this study because of their immature neuronal 
characteristics (ability to proliferate, expression of immature neuronal 
markers). Bilirubin treatment decreased cellular viability as measured by 
the MTT assay. The decrease in viability of cells was accompanied by 
the increase in the level of the double-stranded break marker, ϒ-H2AX. 
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NAC co-treatment results strongly demonstrated the role of oxidative 
stress in the bilirubin induced DNA damage.  
 
To the best of our knowledge, bilirubin induced DNA damage has never 
been studied in patients with Crigler-Najjar syndrome. Previous studies 
performed in peripheral blood cells derived from babies with neonatal 
hyperbilirubinemia demonstrated the presence of DNA damage after 
intensive phototherapy treatment. However, the study results were 
controversial when DNA damage was compared between untreated (or 
pre-phototherapy) jaundiced babies with control normal groups 
(Karadag et al., 2010; Karakukcu et al., 2009 ; Ramy et al., 2016; Tatli 
et al., 2008; Yahia et al., 2015). Additionally, all these studies were 
done in peripheral blood cells that may have different sensitivity to 
bilirubin-induced toxicity when compared with neuronal cells. 
Work done by other labs showed increased level of 8-OH G level in 
neonates with lower bilirubin level (Basu et al., 2014). Peripheral blood 
mononuclear cells (PBMCs) treated with bilirubin showed higher rate of 
DNA strand breakage (Khan and Poduval, 2012). MTT assay confirmed 
the bilirubin induced toxicity in SH SY 5Y cells (Qaisiya et al., 2017a; 
Qaisiya et al., 2014). Prolonged exposure (more than 4h) activates some 
type of protective mechanism in SH SY 5Y cells (Tiribelli’s lab, 
unpublished results). We showed a time dependent induction of DNA 
damage after bilirubin treatment. DNA damage starts 24h post-bilirubin 
treatment that further accumulates over time. Previous study also 
showed accumulation of ϓ-H2AX foci after 24h of bilirubin treatment. 
BrDU labelling and pulse-chase experiments showed slower progression 
of cells through the S-phase post-bilirubin treatment (Deganuto et al., 
2010). Our NAC co-treatment results proved the direct role of oxidative 
stress in bilirubin induced DNA damage. Bilirubin exposure leads to 
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higher levels of the marker of oxidative DNA damage 8-OH G and 
abasic sites in SH SY 5Y cells (Deganuto et al., 2010). The co-treatment 
of SH SY 5Y cells with bilirubin and NAC increases the viability, 
suggesting oxidative stress as an important factor for bilirubin toxicity 
(Deganuto et al., 2010) 
The bilirubin-induced DNA damage had no effect on the levels of P53. 
These results are in contrast to studies performed in colon cancer cells 
(Ollinger et al., 2007). Colon cancer cells up-regulate P53 levels after 
treatment with bilirubin. Cell cycle analysis showed the accumulation of 
cells in G1-phase of the cell cycle. However, DNA damage was never 
checked in that study (Ollinger et al., 2007). The differential levels of 
P53 regulation in two studies may be due to the use of cell lines with 
different origins (SH SY 5Y vs Colon cancer cell line). However, we 
cannot rule out the possible activation of P53 independent sub-
pathways. Other sub-pathways of DNA damage response were not 
addressed in this study. Bilirubin acts as a pro-oxidant at high Bf levels 
and kills neuronal cells. Neuronal cells are extremely susceptible to 
oxidative stress due to low GSH storage (Brito et al., 2008b). Reduced 
expression of antioxidant enzymes like superoxide dismutase, catalase, 
and glutathione peroxidase, compared to other tissues, accompanied by 
higher levels of unsaturated fatty acids that are prime target of lipid 
peroxidation, make neuronal cells extremely susceptible to oxidative 
stress (Aoyama et al., 2008). In vivo studies in hyperbilirubinemic mice 
showed cerebellum as the most severely affected part of the brain due to 
its post-natal development (Bortolussi et al., 2014a; Conlee and Shapiro, 
1997). Studies from our group also showed the impairment of anti-
oxidant defenses in the cerebellum of mutant mice (Bortolussi et al., 
2015), strongly supporting the hypothesis of increased oxidative stress 
in those animals, consequent to hyperbilirubinemia. However, further 
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studies are required to determine the extent of DNA damage in the 
cerebellum of those animals.  
The work presented in this thesis showed the potential DNA damaging 
activity of bilirubin. These results are particularly important for persons 
with hyperbilirubinemia conditions, which may put them at risk of 
mutagenesis and tumor development. Although no significant DNA 
damage was evident in Gilbert patients and Gunn rats (Wallner et al., 
2013), we lack information from patients with cronically higher plasma 
bilirubin levels, such as Crigler-Najjar type I and type II patients. In 
many cases, these patients undergo liver transplantation early during 
life, restricting the availability of information regarding potential 
carcinogenesis due to uncontrolled hyperbilirubinemia for a longer 
period of time. 
The analysis of potential carcinogenesis is also limited by the life-long 
immunosuppression to avoid organ rejection, which increases the risk of 
cancer development. (Haagsma et al., 2001; Herrero et al., 2005). Our 
results may prove to be important for CNS patients who have not 
undergone liver transplantation during early age. These patients may get 
exposed to chronic high level of bilirubin, with sporadic spikes of very 
high levels of plasma bilirubin, due to decreased efficiency of 
phototherapy during growth and puberty (Sellier et al., 2012),  putting 
them at risk of DNA damage. In fact, the accumulation of DNA lesions 
in other scenarios contributes to neuronal cell death (Chan, 2001), a 
phenomenon observed in specific regions of the brain both in 
hyperbilirubinemic patients and rodent animal models (Bortolussi et al., 
2014a; Bortolussi et al., 2015; Shapiro et al., 2006). 
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4.2 Effect of bilirubin on DNA repair pathway 
In this study, we have shown for the first time the effect of bilirubin on 
HR and NHEJ. We started these experiments based on our previous 
observations that TALEN that were very efficient in cell lines, did not 
apparently function in vivo, in the liver of hyperbilirubinemic Ugt1 
knockout animals. So, eventually, based on these observations, we 
investigated the effects of bilirubin on HR and NHEJ pathways. We 
hypothesized the bilirubin may acts as negative regulator of DNA repair 
in Ugt1 KO mice due to several reasons, such as, probable effect on cell 
cycle, reduction in expression of some of the DNA repair proteins and 
preventing the loading of repair proteins onto the damaged DNA 
template. 
 Bilirubin-induced toxicity in HeLa DR GFP cells was confirmed by the 
MTT assay. Previous studies also showed the toxicity of bilirubin in 
HeLa cells (Cesaratto et al., 2007). As discussed before, exposure to 
bilirubin leads to oxidative stress in human cells. Here, in contrary to 
our expectations, we showed dose-and time-dependent increase in HR 
by bilirubin. Treatment with the antioxidant NAC demonstrates the 
involvement of oxidative stress in the modulation of HR. Treatment 
with bilirubin also modulated the NHEJ pathway. DNA damage analysis 
in HeLa cells showed the induction of DNA damage after treatment with 
bilirubin. Investigation of the effect of bilirubin on cell cycle showed no 
effect on any phase of the cell cycle.  
The work presented in this thesis showed dose-dependent induction of 
HR by bilirubin, with maximum increase (1.8-2 folds) at pathologically 
relevant Bf concentration, i.e., 140 nM Bf. The modulation of HR by 
NAC proved the role of oxidative stress in HR. Studies in yeast, 
Saccharomycess cerevisiae showed important role of HR in recovery of 
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cells from oxidative DNA damage  (Hayashi and Umezu, 2017; Yi et 
al., 2016). Similarly, N, N- dimethylformamide-induced oxidative stress 
leads to oxidative DNA damage and induction of HR in human cells 
(Wang et al., 2016). Another study showed the importance of HR in the 
rescue of stalled replication forks due to endogenous oxidative stress 
(Wilhelm et al., 2016). DNA damage analysis showed induction of 
DNA damage by bilirubin in HeLa cells, as seen in SH SY 5Y cell in 
this work and another study (Deganuto et al., 2010). However, cell cycle 
analysis of HeLa cells post bilirubin treatment showed unperturbed cell 
cycle phases. These results are in contrast to the results shown in 
previous study using SH SY 5Y cells (Deganuto et al., 2010). We 
hypothesize that modulation of HR is a general mechanism that gets 
activated after induction of DNA damage by bilirubin. Another pathway 
of DSB repair that can be activated after DNA damage is NHEJ. Indeed, 
using a non-homologous recombination substrate, we have also shown 
modulation of NHEJ by bilirubin. However, the in vivo scenario may be 
completely different. Our study is supported by other studies in prostate 
cancer. This study showed NHEJ as a main player behind gene fusion in 
prostate cancer by inflammation-induced oxidative stress (Mani et al., 
2016). Similarly, another study showed activation of NHEJ by oxidative 
stress (Sharma et al., 2016). 
Our recent work in Ugt1 KO mice showed different susceptibility of 
brain and liver tissues to high bilirubin levels. In this mouse model, 
there was a time dependent increase in DNA damage in cerebellum, 
with no DNA damage in liver tissues (unpublished results from Dr. 
Muro’s group). These results are particularly important, proved that 
different tissues respond differentially to bilirubin induced oxidative 
stress.  
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In conclusion, bilirubin-induced oxidative stress leads to DNA damage 
in neuronal cells. In addition, bilirubin-induced DNA damage has a 
general effect on both types of DNA repair pathways: HR and NHEJ 
pathway in HeLa cells. 
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4.3 Future directions 
In the future, more detailed analysis of the signalling mechanisms 
activated by bilirubin induced DNA damage in SH SY 5Y and HeLa 
cells will be done. More specifically, activation of the two most 
important kinases and their different downstream targets that gets 
activated after ssDNA (ATR) and dsDNA (ATM) breaks will be 
studied. 
In addition, more detailed analysis on the DNA damaging activity of 
bilirubin will be performed in neonate mice of the hyperbilirubinemic 
model generated in our lab (Bortolussi et al., 2012). The most 
interesting organs to analyse are the cerebellum and the liver. The 
cerebellum represents the most severely affected part in the brain, 
consequent to increased bilirubin-induced toxicity during its post-natal 
development. However, we do not rule out the presence of DNA 
damage in other brain regions. DNA damage by bilirubin could be also 
present in the liver of jaundiced mice, consequent to the high level of 
tissue bilirubin present in the acute phases of the disease, which is 
approximately 10 fold of the concentration found in the cerebellum 
(Bortolussi et al., 2014b).  
Many different pathways are activated by bilirubin both in vitro and in 
vivo leading to neurodegeneration and brain damage, such as 
inflammation, oxidative stress and ER stress, but how DNA damage 
interacts with those mechanisms is not yet defined. Treatment of 
hyperbilirubinemic mice with NAC may also provide very important 
mechanistic information of bilirubin toxicity in vivo. 
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In this part of thesis, we planned to work on two different projects. In 
the first project, we planned to correct the one-base deletion present in 
the Ugt1 knockout strain using NcoI restriction site targeting TALEN 
pair previously designed and tested in our laboratory (Porro et al., 
2014). In the second project, we decided to perform hi-throughput 
miRNA screening to find out miRNAs modulating HR in a liver cell 
line. The HR modulating miRNA discovered in the hi-throughput 
screening was further planned to be tested in vivo in order to increase 
the gene-targeting efficiency in vivo. 
 
4.4 TALEN mediated correction of Ugt1 Knockout mice model 
Our previous attempts to correct the Ugt1 knockout model using 
previously tested NcoI targeting TALEN pairs failed. We hypothesized 
that the failure could be due to two main problems. First, we 
hypothesized that during previous attempts, the pAAV donor vector 
used by us possibly had some cryptic splicing site. This led us to design 
new human-codon optimized donor vector. In this work, we successfully 
cloned the new donor DNA in the rAAV vector. This new donor vector 
was not tested in vivo, as the TALEN activity was very low in vivo. 
Secondly, we hypothesized that the TALEN activity in vivo was very 
low compared to our previous in vitro studies. So, we decided to check 
the activity of NcoI targeting TALEN pair in vivo. In order to check the 
activity of TALENs in vivo, wild type mice were injected with AAV 
virus encapsulating NcoI restriction site targeting TALEN pair. 
Genomic PCR followed by NcoI site restriction analysis from the 
genomic DNA derived from the liver of injected animals showed the 
absence of any NcoI resistant band. However, this result cannot explain 
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the low or absent activity of TALENs in vivo, given the high activity 
observed in vivo using the reporter system. Several different types of 
analysis could have been done to analyse the functionality of TALENs 
in vivo. One of the possible experiment that could have been done was 
checking the expression of TALEN in liver of mice after injection. Real 
time qPCR was one of the options to check the expression of TALEN 
pair in the liver of injected mice. However, real time qPCR was 
impossible to perform in order to check the expression of TALEN due 
to high level of similarity between right and left arm of TALENs. 
Another possibility to check the expression of TALENs in liver is by 
tagging TALEN pairs with two different tags such as FLAG and HA 
tag. Unfortunately, we used the Golden-Gate system (Cermak et al., 
2011) to generate the TALENS, which did not have plasmids containing 
the tags in the TALEN pairs. 
Due to several non-conclusive results, we decided to stop this project. 
We also planned to test the CRISPR/Cas9 system to correct the Ugt1 
KO mice. The design and cloning of 4 different gRNAs was done. The 
activity of all the gRNAs was tested using the reporter vector used in 
our previous work to check the activity of TALEN. Unexpectedly, the 
activity of all the 4 gRNAs in transfected cells was always lower than 
NcoI targeting TALENs. The reason for the lower gRNA activity 
compared to TALEN was not clear; therefore, we decided not to 
proceed with the CRISPR/Cas9 system to correct the Ugt1 mutation in 
the KO mouse strain. 
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4.5 Hi-throughput miRNA screening to identify novel modulators of 
homologous recombination 
To perform hi-throughput miRNA screening, we decided to prepare the 
FlipIN HEK293 stable cell line using reporter vector designed by our 
lab during our previous study (Porro et al., 2014). So, we subcloned the 
reporter insert into the pcDNA5/FRT plasmid to make FlipIN stable cell 
clones. However, later on we realized that HEK293 cells could not be 
used for hi-throughput screening due to the partial removal of cells from 
the wells during transfection and other processing events, necessary 
during the miRNA highthroughput analysis procedure. So, we decided 
to generate the stable clones in Hep3B background. In parallel, cloning 
of reporter insert was done in pcDNA3 vector also due to the fact that 
pcDNA5/FRT plasmid that we cloned previously does not contain any 
antibiotic resistance gene. Several different stable clones were generated 
and the luciferase activity of all the clones was checked after TALEN 
transfection.  
Later on, through literature search, we discovered that the reporter 
plasmid used to generate stable clones, is mainly repaired by the single 
stranded annealing (SSA) mechanisms instead of HR (Bhargava et al., 
2016). In parallel, another member of the laboratory prepared a substrate 
specific for analyzing HR events, but since the recombination efficiency 
appeared to be too low to be used in a screening analysis, we decided to 
interrupt this project. The correct strategy that we should be using from 
the beginning to perform hi-througput screening in DR-GFP stable cell 
clones used extensively in HR research field. However, these cells are 
not of liver origin and results may not be directly applicable in a liver 
context, requiring further confirmation experiments.
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CONCLUSIONS 
Better understanding of the mechanisms responsible for bilirubin-
induced neurotoxicity is very important for the treatment and 
management of BIND. Oxidative stress is one of the main mechanisms 
responsible for bilirubin-induced neurotoxicity.  
In the first part of this thesis, I have shown the time-dependent increase 
in DNA damage in neuronal cell line after treatment with bilirubin. 
Treatment with the antioxidant NAC reduced DNA damage, strongly 
suggesting the key role of oxidative stress in bilirubin-induced DNA 
damage.  
In the second part of this thesis, I have shown the effect of bilirubin on 
DSB repair pathways. Bilirubin treatment led to dose-dependent 
increase in homologous recombination. NAC treatment reversed the 
increase in HR, which suggests the important role of oxidative stress 
behind the bilirubin-induced increase in HR. DNA damage analysis 
showed the increase in DNA damage after bilirubin treatment also in 
HeLa cells. Furthermore, bilirubin treatment also modulated NHEJ. 
Based on these result, I conclude that treatment with bilirubin led to 
increased DNA damage, which further activated both the NHEJ and HR 
DSB repair pathways. 
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